GWG Holdings, Inc. Form 10-Q November 13, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

For the transition period from ______ to _____

Commission File Number: 001-36615

GWG HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware26-2222607(State or other jurisdiction of(I.R.S. Employer)

incorporation or organization) Identification No.)

220 South Sixth Street, Suite 1200

Minneapolis, MN 55402

(Address of principal executive offices, including zip code)

(612) 746-1944

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 13, 2014, GWG Holdings, Inc. had 5,870,193 shares of common stock outstanding.

GWG HOLDINGS, INC.

Index to Form 10-Q

for the Quarter Ended September 30, 2014

		Page
PART I.	FINANCIAL INFORMATION	No.
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of September 30, 2014, and December 31, 2013 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013	3 4
	Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2014 and 2013 Condensed Consolidated Statements of Stockholders' Equity Notes to Condensed Consolidated Financial Statements	5-6 7 8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	31
Item 4.	Controls and Procedures	51
PART II.	OTHER INFORMATION	52
Item 1A	.Risk Factors	52
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	53
Item 6.	Exhibits	54
SIGNAT	ſURES	55

2

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GWG HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2014 (unaudited)	December 31, 2013
ASSETS Cash and cash equivalents Restricted cash Investment in life settlements, at fair value Other assets TOTAL ASSETS	\$29,511,989 2,144,734 276,381,979 3,453,974 \$311,492,676	\$33,449,793 5,832,970 234,672,794 1,424,919 \$275,380,476
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) LIABILITIES Revolving credit facility Series I Secured notes payable Renewable Secured Debentures Interest payable Accounts payable and other accrued expenses Deferred taxes, net TOTAL LIABILITIES	\$79,000,000 27,701,842 169,186,917 9,768,218 2,069,386 3,545,504 291,271,867	\$79,000,000 29,275,202 131,646,062 7,209,408 1,343,952 7,675,174 256,149,798
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (par value \$0.001; shares authorized 40,000,000; shares issued and outstanding 3,368,109; liquidation preference of \$25,261,000 on December 31, 2013)	-	24,722,693
STOCKHOLDERS' EQUITY (DEFICIT) CONVERTIBLE, REDEEMABLE PREFERRED STOCK (par value \$0.001; shares authorized 40,000,000; shares issued and outstanding 2,710,214; liquidation preference of \$20,327,000 on September 30, 2014)	20,217,836	-
COMMON STOCK (par value \$0.001: shares authorized 210,000,000; 5,871,798 shares issued and 5,870,193 shares outstanding on September 30, 2014 and 4,562,000 shares both issued and outstanding on December 31, 2013)	5,870	4,562

Additional paid-in capital	16,323,738	2,942,000
Accumulated deficit	(16,326,635)	(8,438,577)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	20,220,809	(5,492,015)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	\$311,492,676	\$275,380,476

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months	s Ended	Nine Months I	Ended	
	September 30, 2014	September 30, 2013	September 30, 2014	September 30 2013	,
REVENUE	-		-		
Gain on life settlements, net	\$5,118,423	\$ 5,437,580	\$16,119,517	\$21,511,182	
Interest and other income	10,229	89,927	23,975	3,531,922	
TOTAL REVENUE	5,128,652	5,527,507	16,143,492	25,043,104	
EXPENSES					
Employee compensation and benefits	1,376,710	1,100,159	3,524,274	4,101,502	
Legal and professional fees	760,130	420,874	1,627,769	1,134,181	
Interest expense	6,796,736	5,537,326	19,731,327	14,946,484	
Other expenses	1,453,367	755,066	3,277,850	2,955,237	
TOTAL EXPENSES	10,386,943	7,813,425	28,161,220	23,137,404	
INCOME (LOSS) BEFORE INCOME TAXES	(5,258,291)	(2,285,918) (12,017,728)	1,905,700	
INCOME TAX (BENEFIT) EXPENSE	(1,858,100)) (4,129,670)		
NET INCOME (LOSS)	\$(3,400,191)	\$ (1,628,950) \$(7,888,058)	\$ 194,874	
Accretion of preferred stock to liquidation value	(117,674	(191,663) (344,658)	(658,303)
LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	\$(3,517,865)	\$(1,820,613)) \$(8,232,716)	\$ (463,429)
NET LOSS PER SHARE	¢ (0.7(¢ (0.40	φ(1.00)	φ (0.10	`
Basic Dilate 1	· · · · · · · · · · · · · · · · · · ·		· · · ·	\$ (0.10)
Diluted	\$(0.76	\$ (0.24) \$(1.80	\$ (0.06)
WEIGHTED AVERAGE SHARES OUTSTANDING					
Basic	4,633,097	4,562,000	4,579,920	4,867,962	
Diluted	4,633,097	7,489,000	4,579,920	7,803,947	

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	Three Months September 30, 2014	Ended September 30, 2013	Nine Months E September 30, 2014	nded September 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to net cash flows from operating activities:	\$(3,400,191)	\$(1,628,950)	\$(7,888,058)	\$ 194,874
Life settlements – change in fair value Amortization of deferred financing and issuance costs	(8,761,912) 863,217	(6,960,335) 1,125,913	(30,973,250) 2,570,881	(25,904,240) 3,056,793
Deferred income taxes Convertible, redeemable preferred stock dividends	(1,858,100) 186,182	(655,968) 185,231	(4,129,670) 575,513	1,710,826 443,486
payable (Increase) decrease in operating assets: Other assets Increase in operating liabilities:	(847,221)		(2,096,140)	(3,181,461)
Accounts payable and accrued expenses	490,496	470,395	3,658,659	2,168,874
NET CASH FLOWS USED IN OPERATING ACTIVITIES	(13,327,529)	(7,031,043)	(38,282,065)	(21,510,848)
CASH FLOWS FROM INVESTING ACTIVITIES Investment in life settlements Proceeds from settlement of life settlements NET CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES	(680,000) 930,625 250,625	(14,030,797) 1,331,743 (12,699,054)	999,125	(26,916,790) 4,203,895 (22,712,895)
CASH FLOWS FROM FINANCING ACTIVITIES Net proceeds from revolving credit facility Payments for redemption of Series I Secured notes	- (509,004)	- (2,311,710)	- (2,047,928)	8,000,000 (6,242,586)
payable Proceeds from issuance of Renewable Secured Debentures	15,281,809	19,617,094	48,516,296	62,056,755
Payments for issuance costs and redemption of Renewable Secured Debentures	(4,494,383)	(4,305,558)	(13,816,794)	(9,642,129)
Proceeds from (uses of) restricted cash Issuance (repurchase) of common stock	665,699 9,030,000 (445,183)	954,217 - (35,285)	3,688,236 9,030,000) (465,239)	(1,416,558) (3,252,400) (347,089)

Redemptions of convertible, redeemable preferred stock				
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	19,528,938	13,918,758	44,904,571	49,155,993
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	6,452,034	(5,811,339) (3,937,804)	4,932,250
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD END OF PERIOD	23,059,955 \$29,511,989	38,240,633 \$32,429,294	33,449,793 \$29,511,989	27,497,044 \$32,429,294

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED

(unaudited)

	Three Month	hs Ended	Nine Months	Ended
	September 30, 2014	September 30, 2013	September 30, 2014	September 30, 2013
SUPPLEMENTAL DISCLOSURES OF CASH FLOW				
INFORMATION				
Interest paid	\$5,095,000	\$ 3,605,000	\$12,877,000	\$10,117,000
NON-CASH INVESTING AND FINANCING				
ACTIVITIES				
Series I secured notes:				
Non-cash conversion of Series I secured notes	\$ -	\$ 350,000	\$ -	\$350,000
Non-cash conversion of accrued interest and commissions payable to principal	\$47,000	\$ 39,000	\$152,000	\$ 190,000
Renewable secured debentures:				
Non-cash conversion of accrued interest and commission payable to principal	\$133,000	\$ 91,000	\$415,000	\$191,000
Convertible, redeemable preferred stock				
Non-cash conversion to common stock	\$4,957,000	\$ -	\$4,957,000	\$ -
Non-cash conversion of dividends payable	\$192,000	\$ 182,000	\$573,000	\$443,000
Non-cash accretion of convertible, redeemable preferred stock to redemption value	\$118,000	\$ 192,000	\$345,000	\$658,000

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

	Preferred Stock Shares	Preferred Stock	Common Shares	Common Stock (par)	Additional Paid-in Capital	Accumulated Deficit	Total Equity
Balance, December 31, 2012	-	\$ -	4,994,500	\$ 4,995	\$6,976,838	\$(8,243,622)	\$(1,261,789)
Net loss	-	-	-	-	-	(194,955)	(194,955)
Repurchase of common stock	-	-	(432,500)) (433)	(3,251,967)) -	(3,252,400)
Issuance of stock options	-	-	-	-	23,753	-	23,753
Accretion of preferred stock to liquidation value	-		-	-	(806,624		(806,624)
Balance, December 31, 2013	-	\$ -	4,562,000	\$ 4,562	\$2,942,000	\$(8,438,577)	\$(5,492,015)
Net loss	-	-	-	-	-	(7,888,058)	(7,888,058)
Issuance of common stock	-	-	800,000	800	8,653,605	-	8,654,405
Conversion of preferred stock	-	-	508,193	508	4,956,591	-	4,957,099
Reclassification of preferred stock from temporary equity to permanent equity due to initial public offering (*)	2,710,214	20,217,836	-	-	-	-	20,217,836
Issuance of stock options	-	-	-	-	116,200	-	116,200
Accretion of preferred stock to	-	-	-	-	(344,658		(344,658)

liquidation value

Balance, September2,710,214\$ 20,217,8365,870,193\$ 5,870\$ 16,323,738\$ (16,326,635)\$ 20,220,80930, 2014

* Subject to the terms of the Certificate of Designation for Series A Convertible Preferred Stock, the listing of our common stock on The Nasdaq Capital Market on September 25, 2014 resulted in the termination of a redemption right in favor of the holders of such preferred stock. Preferred stock that is not redeemable by a shareholder is treated as stockholders' equity as shown in the table above.

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(1) Nature of business and summary of significant accounting policies

Nature of business - GWG Holdings, Inc. (GWG Holdings) and subsidiaries, located in Minneapolis, Minnesota, facilitates the purchase of life insurance policies for its own investment portfolio through its wholly owned subsidiary, GWG Life, LLC (GWG Life), and its subsidiaries, GWG Trust (Trust), GWG DLP Funding II, LLC (DLP II) and its wholly owned subsidiary, GWG DLP Master Trust II (the Trust II). Our wholly owned subsidiary, GWG Broker Services, LLC (Broker Services), was formed to earn fees for brokering policy transactions between market participants. Our wholly owned subsidiary United Lending, LLC (United Lending) and its wholly owned subsidiary United Lending SPV, LLC (United Lending SPV) were formed to finance life settlement premiums and policy loans. All of these entities are legally organized in Delaware. Unless the context otherwise requires or we specifically so indicate, all references in this report to "we", "us", "our", "our Company", "GWG", or the "Company" refer to these entities collectively. GWG Member, LLC, a wholly owned subsidiary formed November 2010 to facilitate the acquisition of policies, has not commenced operations as of September 30, 2014.

Basis of presentation - The condensed consolidated balance sheet as of September 30, 2014, the condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013, and the condensed consolidated statements of cash flows for the three and nine months ended September 30, 2014 and 2013, and the related information presented in these notes, have been prepared by management in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. To the extent that information and notes required by U.S. generally accepted accounting principles for complete financial statements are contained in or are consistent with the consolidated audited financial statements in the Company's Form 10-K for the year ended December 31, 2013, such information and notes have not been duplicated herein. In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The condensed consolidated balance sheet at December 31, 2013 was derived from the audited consolidated financial statements as of that date. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

Use of estimates - The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and

assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The most significant estimates with regard to these consolidated financial statements relates to (1) the determination of the assumptions used in estimating the fair value of the investment in life insurance policies, and (2) the value of deferred tax assets and liabilities.

Life settlements - Financial Accounting Standards Codification ("ASC") 325-30, *Investments in Insurance Contracts*, allows a reporting entity the election to account for its investments in life settlements using either the investment method or the fair value method. The election shall be made on an instrument-by-instrument basis and is irrevocable. Under the investment method, an investor shall recognize the initial investment at the purchase price plus all initial direct costs. Continuing costs (policy premiums and direct external costs, if any) to keep the policy in force shall be capitalized. Under the fair value method, an investor shall recognize the initial investment at the purchase price. In subsequent periods, the investor shall remeasure the investment at fair value in its entirety at each reporting period and shall recognize the change in fair value in current period income net of premiums paid. The Company uses the fair value method to account for all life settlements.

The Company recognizes realized gains (revenue) from life settlement contracts upon one of the two following events:

1) Receipt of death notice or verified obituary of insured

2) Sale of policy and filing of change of ownership forms and receipt of payment

The Company recognizes the difference between the death benefits and carrying values of the policy when an insured event has occurred and the Company determines that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. In an event of a sale of a policy the Company recognizes gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Deposits and initial direct costs advanced on unsettled policy acquisitions are recorded as other assets until policy ownership has been transferred to the Company. Such deposits and direct cost advances were \$25,000 and \$201,000 at September 30, 2014 and December 31, 2013, respectively.

Deferred financing and issuance costs – Costs incurred to obtain financing under the revolving credit facility, as described in note 6, have been capitalized and are amortized using the straight-line method over the term of the revolving credit facility. Amortization of deferred financing costs was \$89,000 for both the three-month periods ended September 30, 2014 and 2013, and \$268,000 and \$365,000 for the nine-month periods ended September 30, 2014 and 2013, respectively. The future amortization is expected to be \$89,000 for the three months ending December 31, 2014. The Series I Secured notes payable, as described in note 7, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Renewable Secured Debentures, as described in note 8, are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A preferred stock, as described in note 9, is reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which are amortized using the interest method as interest expense over the three-year redemption period.

Earnings (loss) per share - Basic per share earnings (loss) attributable to non-redeemable interests is calculated using the weighted-average number of shares outstanding during the period. Diluted earnings per share is calculated based on the potential dilutive impact, if any, of the Company's convertible, redeemable preferred stock, and outstanding warrants, and stock options.

Subsequent events - Subsequent events are events or transactions that occur after the balance sheet date but before consolidated financial statements are issued. The Company recognizes in the consolidated financial statements the effects of all subsequent events that provide additional evidence about conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing the consolidated financial statements. The Company's consolidated financial statements do not recognize subsequent events that provide evidence about conditions that did not exist at the date of the balance sheet but arose after the balance sheet date and before the consolidated financial statements are available to be issued. The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the consolidated financial statements are filed for potential recognition or disclosure.

Recently adopted pronouncements - In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which converges the FASB and the International Accounting Standards Board standard on revenue recognition. Areas of revenue recognition that will be affected include, but are not limited to, transfer of control, variable consideration, allocation of transfer pricing, licenses, time value of money, contract costs and disclosures. This is effective for the fiscal years and interim reporting periods beginning after December 15, 2016. We are currently evaluating the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements or related disclosures.

(2) Restrictions on cash

The Company is required by its lenders to maintain collection and escrow accounts. These accounts are used to fund the acquisition, pay annual premiums of insurance policies, pay interest and other charges under the revolving credit facility, and collect policy benefits. DZ Bank AG, as agent for Autobahn Funding Company, LLC, the lender for the revolving credit facility as described in note 6, authorizes the disbursements from these accounts. At September 30, 2014 and December 31, 2013 there was a balance of \$2,145,000, and \$5,833,000, respectively, maintained in these restricted cash accounts.

(3) Investment in life insurance policies

The life insurance policies (Level 3 fair value measurements) are valued based on unobservable inputs that are significant to the overall fair value measurement. Changes in the fair value of these instruments are recorded in gain or loss on life insurance policies in the consolidated statements of operations (net of the cash premiums paid on the policies). The fair value is determined on a discounted cash flow basis that incorporates life expectancy assumptions. Life expectancy reports have been obtained from widely accepted life expectancy providers. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require. As a result of management's analysis, discount rates of 11.56% and 11.69% were applied to the portfolio as of September 30, 2014 and December 31, 2013.

A summary of the Company's life insurance policies accounted for under the fair value method and their estimated maturity dates, based on remaining life expectancy, is as follows:

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

	As of September 30, 2014			As of December 31, 2013				
Years Ending		Estimated			b Erstimated			
December	of	Fair	Face Value	of	Fair	Face Value		
31,	ContraVtalue				Contra Vta lue			
2014	-	\$-	\$-	-	\$-	\$-		
2015	3	4,936,000	6,000,000	4	5,065,000	6,750,000		
2016	10	10,198,000	14,700,000	8	8,174,000	13,750,000		
2017	21	29,061,000	49,630,000	25	33,345,000	63,916,000		
2018	30	36,645,000	71,167,000	33	37,243,000	80,318,000		
2019	43	46,015,000	109,295,000	34	32,844,000	89,295,000		
2020	40	39,560,000	96,224,000	34	27,741,000	75,644,000		
Thereafter	142	109,967,000	440,948,000	125	90,261,000	410,975,000		
Totals	289	\$276,382,000	\$787,964,000	263	\$234,673,000	\$740,648,000		

The Company recognized policy benefits of \$3,000,000 and \$5,000,000 during the three-month periods ended September 30, 2014 and 2013, respectively, related to policies with a carrying value of \$931,000 and \$1,332,000, respectively. The Company recorded realized gains of \$2,069,000 and \$3,668,000 on such policies. During the nine-month periods ended September 30, 2014 and 2013, the Company recognized policy benefits of \$3,300,000 and \$15,600,000, respectively, related to policies with carrying value of \$999,000 and \$4,204,000, respectively. The Company recorded realized gains of \$2,301,000 and \$11,396,000 on such policies. Subsequent to September 30, 2014, four policies with combined insurance benefits of \$13,000,000 have matured.

Reconciliation of gain on life settlements:

			Nine Months I September 30,	
	2014	2013	2014	2013
Change in fair value	\$8,762,000	\$6,960,000	\$30,973,000	\$25,904,000
Premiums and other annual fees	(5,713,000)	(5,191,000)	(17,155,000)	(15,789,000)
Policy maturities	2,069,000	3,668,000	2,301,000	11,396,000
Gain on life settlements, net	\$5,118,000	\$5,437,000	\$16,119,000	\$21,511,000

The estimated expected premium payments to maintain the above life insurance policies in force through 2018, assuming no mortalities, are as follows:

Years Ending December 31,	
Three months ending December 31,2014	\$6,364,000
2015	26,728,000
2016	29,354,000
2017	32,829,000
2018	35,753,000
	\$131,028,000

Management anticipates funding the estimated premium payments as noted above with proceeds from the DZ Bank revolving credit facility and through additional debt and equity financing as well as from cash proceeds from maturities of life insurance policies. The proceeds of these capital sources are also intended to be used for the purchase, financing, and maintenance of additional life insurance policies.

(4) Fair value definition and hierarchy

ASC 820 establishes a hierarchal disclosure framework which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is affected by a number of factors, including the type of investment, the characteristics specific to the investment and the state of the marketplace including the existence and transparency of transactions between market participants. Assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices in an orderly market generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value. ASC 820 establishes a three-level valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the "exit price") in an orderly transaction between market participants at the measurement date.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The hierarchy is broken down into three levels based on the observability of inputs as follows:

Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary by types of assets and liabilities and is affected by a wide variety of factors, including, for example, whether instrument is established in the marketplace, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by management in determining fair value is greatest for assets and liabilities categorized in Level 3.

Level 3 Valuation Process

The estimated fair value of the Company's life settlements are determined on a quarterly basis by the Company taking into consideration changes in discount rate assumptions, estimated premium payments and life expectancy assumptions, as well as any changes in economic and other relevant conditions. These inputs are then used to estimate the discounted cash flows using the Model Actuarial Pricing System (MAPS) probabilistic portfolio pricing model, which estimates the cash flows using various different probabilities and scenarios. The valuation process includes a review by senior management as of each valuation date. Management also engages a third party expert to independently test the accuracy of the valuations using the inputs provided by management.

Life insurance policies represent financial instruments recorded at fair value on a recurring basis. The following table reconciles the beginning and ending fair value of the Company's Level 3 investments in life insurance policies for the three and nine-month periods ending September 30, 2014 and 2013, as follows:

	Three month en	nded	Nine Months ended	
	September 30,	September 30,		
	2014	2013	2014	2013
Beginning balance	\$267,896,000	\$193,892,000	\$234,673,000	\$164,317,000
Purchases	655,000	14,646,000	11,735,000	28,149,000
Maturities (cash in excess of carrying value)	(931,000)	(1,332,000)	(999,000)	(4,204,000)
Net change in fair value	8,762,000	6,960,000	30,973,000	25,904,000
Ending balance	\$276,382,000	\$214,166,000	\$276,382,000	\$214,166,000

The fair value of a portfolio of life insurance policies is based on information available to the Company at the reporting date. Fair value is based upon a discounted cash flow model that incorporates life expectancy estimate assumptions. Life expectancy estimates are obtained from independent, third-party, widely accepted life expectancy estimate providers at policy acquisition. The life expectancy values of each insured, as determined at policy acquisition, are rolled down monthly for the passage of time by the MAPS actuarial software the Company uses for ongoing valuation of its portfolio of life insurance policies. The discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance policies, discount rates observed in the life insurance secondary market, market interest rates, the credit exposure to the insurance company that issued the life insurance policy and management's estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance policies.

11

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

On January 22, 2013, one of the independent medical actuarial underwriting firms we utilize, 21st Services, announced advancements in its underwriting methodology, resulting in revised estimated life expectancy mortality tables for life settlement transactions. We were advised by 21st Services that the changes are very granular and relate to both specific medical conditions and lifestyles of insureds. These changes were the result of the application of additional medical information gathered by 21st Services over a period of time, and which were applied to the inputs and methodologies used to develop the actuarial life expectancies. While we do not believe these revised methodologies indicate the previous estimated life expectancies were inaccurate, we believe the revised methodologies provide additional information that should be considered in updating our estimate of the life expectancies of the insureds within our portfolio. Based upon our evaluation and analysis of data made available by 21st Services, as well as information regarding the insureds within our portfolio, we have estimated the impact of the changes in 21st Services' methodologies for determining life expectancies on a policy-by-policy basis within our portfolio as of December 31, 2012 and applied such changes to the life expectancy inputs used to estimate fair value. We have adjusted the original life expectancies provided by 21st Services based on four factors, the impact of each analyzed individually for each insured in the GWG portfolio. The four factors are gender, anti-selection, age, and primary impairment. GWG applied this set of adjustments to all 21st Services life expectancy reports used in valuation of the portfolio as of December 31, 2012. At that time, the portfolio contained 211 policies on 194 insured lives. Of those 211 policies, 199 were valued using a 21st Services life expectancy report as part of the pricing life expectancy estimate calculation. While the analysis and adjustments were applied on an individual policy basis, the result was an average overall increase in the original life expectancy estimates of 8.67%. We have a standard practice of obtaining two third-party life expectancy estimates for each policy in our portfolio. As a result, the effective change in life expectancy on the portfolio as of December 31, 2012 was an average of approximately 4.33%, which resulted in an aggregate decrease in the fair value of our life settlements portfolio of \$12.4 million as of December 31, 2012. Life expectancy reports by their very nature are estimates.

During 2013, we sought to update our life expectancy estimates from all four of the major independent third-party medical-actuarial underwriting firms (including 21st Services) with updated medical records on all of the 211 policies we originally used a life expectancy report from 21st Services. As of December 31, 2013, we had successfully procured new life expectancy reports on 176 of the 211 policies owned as of December 31, 2012. We experienced ten mortalities in 2013 for which no updated life expectancy reports were necessary. We also had two small face policies (\$1 million face value or less) in our portfolio for which we did not update life expectancy reports. Accordingly, as of September 30, 2014 we had updated our life expectancy estimates based on updated life expectancy reports on all but 10 policies (covering 9 people) in our portfolio that we are still seeking to update.

In order to assess the reasonableness of our adjustments, made effective December 31, 2012, we compared the life expectancy estimates including any adjustments used on December 31, 2012 to the updated life expectancy estimates used on December 31, 2013. Because an additional year has elapsed since the December 31, 2012 date, the older set of

adjusted life expectancy estimates were "rolled down" to shorter numbers based on an actuarial calculation to make them comparable to the updated life expectancy estimates used on December 31, 2013. The average amount of roll down to account for the 12-month passage of time was eight and one-half months.

We concluded that the adjustments we made effective December 31, 2012, were reasonable when we the compared the rolled down life expectancy estimates from December 31, 2012 to the updated life expectancy estimates on December 31, 2013. The average rolled down life expectancy estimate from December 31, 2012 is 80.9 months. The average updated life expectancy estimate obtained from updated life expectancy reports as of December 31, 2013 is 79.4 months, shorter by one and one-half months.

On September 15, 2014, 21st Services announced changes to its mortality tables primarily for insureds age 90 and older, as well as updated adjustment factors designed to better underwrite seniors with multiple impairments. These changes represent small portions of 21st Services' historical underwritings. We expect medical-actuarial underwriting firms to continue improving and refining their underwriting methodology.

12

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The fair value of life insurance policies is estimated using present value calculations of estimated cash flows based on the data specific to each individual life insurance policy. Estimated future policy premium payments are calculated based on the terms of the policy and the premium payment history. The following summarizes the unobservable inputs utilized in estimating the fair value of the portfolio of life insurance policies:

	As of	As of	
	September 30,	December 31,	
	2014	2013	
Weighted average age of insured	82.6	82.1	
Weighted average life expectancy, months*	80.3	87.0	
Average face amount per policy	\$ 2,727,000	\$ 2,816,000	
Discount rate	11.56	% 11.69	%

* Standard life expectancy as adjusted for insured's specific circumstances.

These assumptions are, by their nature, inherently uncertain and the effect of changes in estimates may be significant. The techniques used in estimating the present value of estimated cash flows are derived from valuation techniques generally used in the life settlement industry that include inputs for the asset that are not based on observable market data. The extent to which the fair value could reasonably vary in the near term has been quantified by evaluating the effect of changes in significant underlying assumptions used to estimate the fair value. If the life expectancy estimates were increased or decreased by four and eight months on each outstanding policy and the discount rates were increased or decreased by 1% and 2%, while all other variables are held constant, the fair value of the investment in life insurance policies would increase or (decrease) by the amounts summarized below:

	Changes in fair value of life insurance policies			
Change in life expectancy estimates	plus 8 months	minus 8 months	plus 4 months	minus 4 months
September 30, 2014	\$(38,876,000)	\$40,795,000	\$(19,680,000)	\$20,166,000
December 31, 2013	\$(34,382,000)	\$36,152,000	\$(17,417,000)	\$17,865,000

Change in discount rate	plus 2%	minus 2%	plus 1%	minus 1%
September 30, 2014	\$(24,279,000)	\$28,449,000	\$(12,608,000)	\$13,646,000
December 31, 2013	\$(22,944,000)	\$27,063,000	\$(11,933,000)	\$12,959,000

Other Fair Value Considerations

Carrying value of receivables, prepaid expenses, accounts payable and accrued expenses approximate fair value due to their short-term maturities and low credit risk. The estimated fair value of the Company's Series I Secured notes payable and Renewable Secured Debentures is approximately \$203,920,000 based on a weighted-average market interest rate of 7.16% based on an income approach, the combined face value of these notes is \$201,439,000 as of September 30, 2014. The carrying value of the revolving credit facility reflects interest charged at the commercial paper rate plus an applicable margin. The margin represents our credit risk, and the strength of the portfolio of life insurance policies collateralizing the debt. The overall rate reflects market, and the carrying value of the revolver approximates fair value. All of the financial instruments are level 3 fair value measurements.

The Company has issued warrants to purchase common stock in connection with the issuance of its convertible, redeemable preferred stock. Warrants were determined by the Company as permanent equity. The fair value measurements associated with the warrants, measured at issuance represent level 3 instruments.

As of September 30, 2014:

Month issued	Warrants issued	Fair value per share	Risk free rate	Volatility	Term
December 2011	68,937	\$0.22	0.42%	25.25 %	6 3 years
March 2012	38,130	\$0.52	0.38%	36.20 %	b 3 years
June 2012	161,840	\$1.16	0.41%	47.36 %	b 3 years
July 2012	144,547	\$1.16	0.41%	47.36 %	b 3 years
September 2012	2,500 415,954	\$0.72	0.31%	40.49 %	b 3 years

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Volatility is based upon the weekly percentage change in the stock price of selected comparable insurance companies. In June 2012, we evaluated the comparable companies used, and made certain changes to those used. The percentage change is calculated on the average price of those selected stocks at the weekly close of business for the year preceding the balance sheet date. We compare annual volatility based on this weekly information.

In conjunction with the Company's recent initial public offering the Company issued a warrant for the purchase of up 16,000 shares of the Company's common stock to the underwriters of the initial public offering.

(5) Notes receivable from related parties

As of September 30, 2014 and December 31, 2013, the Company had receivables totaling \$5,000,000 due from an affiliate, Opportunity Finance, LLC, which were fully reserved. Opportunity Finance ceased operations in 2008.

(6) Credit facilities

Revolving credit facility – Autobahn Funding Company LLC

On July 15, 2008, DLP II and United Lending entered into a revolving credit facility pursuant to a Credit and Security Agreement (Agreement) with Autobahn Funding Company LLC (Autobahn), providing the Company with a maximum borrowing amount of \$100,000,000. Autobahn is a commercial paper conduit that issues commercial paper to investors in order to provide funding to DLP II and United Lending. DZ Bank AG Deutsche Zentral-Genossenschaftsbank (DZ Bank) acts as the agent for Autobahn. The original Agreement was to expire on July 15, 2013. On January 29, 2013, GWG Holdings, together with GWG Life and DLP II, entered into an Amended and Restated Credit and Security Agreement with Autobahn, extending the facility expiration date to December 31, 2014, and removing United Lending as a party to the amended and restated agreement. On May 29, 2014, GWG Holdings, together with GWG Life and DLP II, entered into an Restated Credit and Security Agreement with Autobahn and DZ Bank (as committed lender and Agent). The amendment was entered into for the purpose of extending the maturity date for borrowings under the agreement to December 31, 2016. The

amount outstanding under this facility as of both September 30, 2014 and December 31, 2013 was \$79,000,000.

The Agreement requires DLP II to pay, on a monthly basis, interest at the commercial paper rate plus an applicable margin, as defined in the Agreement. The effective rate was 6.22% at September 30, 2014 and 6.19% at December 31, 2013. The weighted average effective interest rate was 6.23% (excluding the unused line fee) for both three months ended September 30, 2014 and 2013. The Agreement also requires payment of an unused line fee on the unfunded amount under the revolving credit facility. The note is secured by substantially all of DLP II assets which consist primarily of life insurance policies.

The Agreement has certain financial and nonfinancial covenants. The Company was in compliance with these covenants at September 30, 2014 and December 31, 2013. The Agreement generally prohibits the Company from:

changing its corporate name, offices, and jurisdiction of incorporation;

changing any deposit accounts or payment instructions to insurers;

changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect;

merging or consolidating with, or selling all or substantially all of its assets to, any third party;

selling any collateral or creating or permitting to exist any adverse claim upon any collateral;

engaging in any other business or activity than that contemplated by the Agreement;

incurring or guaranteeing any debt for borrowed money;

amending the Company's certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event;

removing an independent director on the board of directors except for cause or with the consent of the lender; or making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action.

14

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

In addition, the Company has agreed to maintain (i) a positive consolidated net income on a Non-GAAP basis (as defined and calculated under the Agreement) for each complete fiscal year and (ii) a tangible net worth on a Non-GAAP basis (as defined and calculated under the Agreement) of not less than \$15 million, and (iii) maintain a borrowing base surplus or cash cushion sufficient to pay 12 months of premiums and facility fees.

Consolidated net income and tangible net worth as of and for the four quarters ended September 30, 2014, as calculated under the agreement, was \$20,467,000 and \$78,236,000 respectively.

Advances under the Agreement are subject to a borrowing base formula, which limits the availability of advances based on attributes of policies pledged to the facility. Over-concentration of policies by insurance carrier, over-concentration of policies by insurance carriers with ratings below a AA- rating, and the premiums and facility fees reserve are the three primary factors with the potential of limiting availability of funds on the facility. Total funds available for additional borrowings under the borrowing base formula criteria at September 30, 2014 and December 31, 2013, were \$11,576,000 and \$3,937,000 respectively.

On July 15, 2008, GWG Holdings delivered a performance guaranty in favor of Autobahn pursuant to which it guaranteed the obligations of GWG Life, in its capacity as the seller and master servicer, under the Credit and Security Agreement and related documents. On January 29, 2013 and in connection with the Amended and Restated Credit and Security Agreement, GWG Holdings delivered a reaffirmation of its performance guaranty. The obligations of GWG Holdings under the performance guaranty and subsequent reaffirmation do not extend to the principal and interest owed by DLP II as the borrower under the credit facility.

(7) Series I Secured notes payable

Series I Secured notes payable have been issued in conjunction with the GWG Series I Secured notes private placement memorandum dated August 25, 2009 (last revised November 15, 2010). On June 14, 2011, the Company closed the offering to additional investors; however, existing investors may elect to continue advancing amounts outstanding upon maturity subject to the Company's option. Series I Secured notes have maturity dates ranging from six months to seven years with fixed interest rates varying from 5.65% to 9.55% depending on the term of the note. Interest is payable monthly, quarterly, annually or at maturity depending on the terms of the note. At September 30,

2014 and December 31, 2013, the weighted-average interest rate of Series I Secured notes was 8.37% and 8.35%, respectively. The notes are secured by assets of GWG Life. The principal amount outstanding under these Series I Secured notes was \$28,193,000 and \$29,744,000 at September 30, 2014 and December 31, 2013, respectively. The difference between the amount outstanding on the Series I Secured notes and the carrying amount on the consolidated balance sheet is due to netting of unamortized deferred issuance costs. Overall, interest expense includes amortization of deferred financing and issuance costs of \$126,000 and \$427,000 for the three and nine months ended September 30, 2014, respectively, and \$165,000 and \$606,000 for the three and nine months ended September 30, 2013, respectively. Future expected amortization of deferred financing costs is \$491,000 over the next six years.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Future contractual maturities of Series I Secured notes payable at September 30, 2014 are as follows:

Years Ending December 31,	
Three months ending December 31,2014	\$1,925,000
2015	12,729,000
2016	8,217,000
2017	4,427,000
2018	754,000
Thereafter	141,000
	\$28,193,000

(8) Renewable Secured Debentures

The Company has registered with the Securities and Exchange Commission, effective January 2012, the offer and sale of \$250,000,000 of secured debentures. Renewable Secured Debentures have maturity dates ranging from six months to seven years with fixed interest rates varying from 4.75% to 9.50% depending on the term of the note. Interest is payable monthly, annually or at maturity depending on the terms of the debenture. At September 30, 2014 and December 31, 2013, the weighted-average interest rate of Renewable Secured Debentures was 7.49% and 7.53%, respectively. The debentures are secured by assets of GWG Life and GWG Holdings. The amount outstanding under these Renewable Secured Debentures was \$173,245,000 and \$134,891,000 at September 30, 2014 and December 31, 2013, respectively. The difference between the amount outstanding on the Renewable Secured Debentures and the carrying amount on the consolidated balance sheets is due to netting of unamortized deferred issuance costs and cash receipts for new issuances in process. Amortization of deferred issuance costs was \$829,000 and \$2,584,000 for the three and nine months ended September 30, 2014, respectively, and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively, and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively, and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively, and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively, and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, respectively and \$630,000 and \$1,253,000 for the three and nine months ended September 30, 2014, re

The use of proceeds from the issuances of Renewable Secured Debentures is limited to the following: (1) payment of commissions on sales of Renewable Secured Debentures, (2) payment of offering expenses, (3) purchase of life insurance policies, (4) payment of premiums on life insurance policies, (5) payment of principal and interest on Renewable Secured Debentures, (6) payment of portfolio operations expenses, and (7) for general working capital.

Future contractual maturities of Renewable Secured Debentures at September 30, 2014 are as follows:

Years Ending December 31,	
Three months ending December 31, 2014	\$16,086,000
2015	55,676,000
2016	43,434,000
2017	21,950,000
2018	10,730,000
Thereafter	25,369,000
	\$173,245,000

The Company entered into an indenture effective October 19, 2011 with GWG Holdings as obligor, GWG Life as guarantor, and Bank of Utah as trustee for the benefit of the debenture holders. The Indenture has certain financial and nonfinancial covenants. The Company was in compliance with these covenants at September 30, 2014 and December 31, 2013.

16

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(9) Convertible, redeemable preferred stock

The Company offered 3,333,333 shares of convertible redeemable preferred stock (Series A preferred stock) for sale to accredited investors in a private placement on July 31, 2011. The offering of Series A preferred stock concluded on September 2, 2012 and resulted in 3,278,000 shares being issued for gross consideration of \$24,582,000. As of September 30, 2014, 248,000 shares have been issued as a result of conversion of \$1,735,000 in dividends into shares of Series A preferred stock and 678,000 shares have been converted to 508,000 shares of the Company's common stock. The Series A preferred stock was sold at an offering price of \$7.50 per share. Series A preferred stock has a preferred yield of 10% per annum, and each share has the right to convert into 0.75 shares of the Company's common stock. Series A preferred shareholders also received three-year warrants to purchase, at an exercise price per share of \$12.50, one share of common stock for every 40 shares of Series A preferred stock purchased. The warrants are exercisable immediately. Upon their original issuance, these warrants had a three-year exercise period. Effective August 1, 2014, the Board of Directors authorized the extension of the warrant exercise period for an additional two years. In the Certificate of Designations for the Series A preferred stock dated July 31, 2011, the Company has agreed to permit preferred shareholders to sell their shares back to the Company for the stated value of \$7.50 per share, plus accrued dividends, according to the following schedule:

Up to 33% of the holder's unredeemed shares one year after issuance: Up to 66% of the holder's unredeemed shares two years after issuance; and Up to 100% of the holder's unredeemed shares three years after issuance.

The Company's obligation to redeem Series A preferred shares terminated upon the Company completing a registration of its common stock with the SEC which occured on September 24, 2014 (See Note 11). As such, the convertible redeemable preferred stock was reclassified from temporary equity to permanent equity. The Company may redeem the Series A preferred shares at a price equal to 110% of their liquidation preference (\$7.50 per share) at any time after December 15, 2012. As of September 30, 2014, the Company had redeemed an aggregate of 145,000 shares of Series A preferred stock.

The Series A preferred shares (i) were convertible, at the election of the Company, into common stock of the Company in the event of either a registered offering of the Company's common stock with the SEC aggregating gross proceeds of at least \$5.0 million and at a price equal to or greater than \$11.00 per share; (ii) remain convertible at the option of each holder; and (iii) are required to be converted upon the consent of shareholders holding at least a majority of the then-outstanding Series A preferred stock. In connection with the Company's initial public offering,

the Company elected to cause the conversion of 677,566 shares of preferred stock into 508,193 shares of common stock. As of September 30, 2014, the Company had 2,710,000 shares of Series A preferred stock outstanding with gross consideration of \$20,327,000 (including cash proceeds, conversion of Series I Secured notes and accrued interest on Series I notes, and conversion of preferred dividends payable). The Company incurred Series A preferred stock issuance costs of \$2,838,000, of which \$2,729,000 was amortized to additional paid in capital through September 30, 2014, resulting in a carrying amount of \$20,218,000.

The Company determined that the grant date fair value of the outstanding warrants attached to the Series A preferred stock was \$395,000 for warrants outstanding as of September 30, 2014. The Company may redeem outstanding warrants prior to their expiration, at a price of \$0.01 per share upon 30 days written notice to the investors at any time after (i) the Company has completed a registration of its common stock with the SEC and (ii) the volume of weighted-average sale price per share of common stock equals or exceeds \$14.00 per share for ten consecutive trading days ending on the third business day prior to proper notice of such redemption. Total warrants outstanding as of September 30, 2014, were 415,955 with a weighted-average remaining life of 2.59 years. Total warrants outstanding at December 31, 2013, were 415,955 with a weighted-average remaining life of 1.34 years. As of September 30, 2014, none of these warrants have been exercised.

Dividends on the Series A preferred stock may be paid in either cash or additional shares of Series A preferred stock at the election of the holder and approval of the Company. The dividends are reported as an expense and included in the caption interest expense in the consolidated statements of operations. The Company declared and accrued dividends of \$632,000 during both the three months ended September 30, 2014 and 2013, and \$1,912,000 and \$1,897,000 during the nine months ended September 30, 2014 and 2013, respectively, pursuant to a board resolution declaring the dividend. 27,000 and 26,000 shares of Series A preferred stock were issued in lieu of cash dividends in the three month periods ended September 30, 2014 and 2013, and \$3,000 shares of Series A preferred stock were issued in lieu of cash dividends in the nine-month periods ended September 30, 2014 and 2013, respectively. The shares issued in lieu of cash dividends were issued at \$7.00 per share. As of September 30, 2014, GWG Holdings has \$632,000 of accrued preferred dividends which were paid or converted to shares of Series A preferred stock on October 15, 2014.

(10) Income taxes

For the three and nine months ended September 30, 2014, the Company recorded income tax benefit of \$1,858,000 and \$4,130,000, or 35.3% and 34.4%, respectively, of income before taxes, compared to the recognition of an income tax benefit of \$657,000, or 28.7% of income before taxes for the three months ended September 30, 2013 and recording an income tax expense of \$1,711,000, or 89.8% of income before taxes, for the nine months ended September 30, 2013. The primary differences between the Company's September 30, 2014 effective tax rate and the statutory federal rate are the accrual of nondeductible preferred stock dividend expense of \$1,912,000, state taxes, and other non-deductible expenses.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance policies and revenue recognition with respect to the mark-to-market of life insurance portfolio.

(11) Common Stock

On September 24, 2014, GWG consummated an initial public offering of its common stock which resulted in the sale of 800,000 shares of common stock at \$12.50 per share. The sale resulted in net proceeds of approximately \$9.03 million after the deduction of underwriting commissions, discounts and expense reimbursements. In connection with this offering, the Company started listing its common stock on The NASDAQ Capital Market under the ticker symbol "GWGH" effective September 25, 2014. The Company intends to use the net proceeds from the offering to promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in the secondary market for life insurance policies, purchase additional life insurance policies in the secondary market, pay premiums on the Company's life insurance policy assets, fund its portfolio operations, and for working capital purposes.

On July 11, 2011, we entered into a Purchase and Sale Agreement with Athena Securities Group, Ltd. and Athena Structured Funds PLC. Under this agreement, we issued to Athena Securities Group, Ltd. (Athena) 494,500 shares of common stock, which was equal to 9.9% of our outstanding shares, in exchange for shares equal to 9.9% of the outstanding shares in Athena Structured Funds, PLC and cash of \$5,000. This 2011 agreement had contemplated cooperative efforts by the parties aimed at developing a security and related offering in Europe or Ireland, the proceeds of which would be used to finance the acquisition of life-insurance related assets in the United States. In 2013, we sought to terminate the 2011 agreement due to a changing regulatory environment in Europe that negatively affected the likelihood of consummating the contemplated offering of securities, and our dissatisfaction with Athena's performance under the 2011 agreement. As a result, in June 2013 we entered into a second Purchase and Sale Agreement with Athena Securities Ltd. and Athena. This agreement effected the termination of the 2011 agreement. The June 2013 agreement contained mutual general releases of claims and substantially unwound certain capital stock transactions that had been effected under the 2011 agreement. In particular, Athena returned to us for redemption 432,500 shares of our common stock, and retained 62,000 common shares in recognition of their earlier efforts under the 2011 agreement. For our part, we sold back to Athena all of our ownership in Athena Structured Funds, PLC that we had originally acquired under the 2011 agreement. Presently, we have no ongoing business relationship with Athena.

Stock split— On June 24, 2014, the Company's Board of Directors and majority stockholders approved a joint resolution to effect an amendment to the Company's Certificate of Incorporation to effect a reverse split of the issued and outstanding common stock on a 2-for-1 basis. The effective date of the amendment and reverse stock split was June 24, 2014. In lieu of fractional shares, stockholders received cash payments in an amount equal to the fraction to which the stockholder would otherwise be entitled multiplied by the price of the common stock, as determined by the Board of Directors of the Corporation, but adjusted so as to give effect to the reverse stock split. The par value of the common stock remained at \$0.001 per share.

(12) Stock Incentive Plan

The Company adopted the GWG Holdings, Inc. 2013 Stock Incentive Plan on March 27, 2013. The plan is administered by Compensation Committee of the Board of Directors of the Company. The Company's Chief Executive Officer may, on a discretionary basis and without committee review or approval, grant incentives to new employees of the Company who are not Officers of the Company. Incentives under the plan may be granted in one or a combination of the following forms: (a) incentive stock options and non-statutory stock options; (b) stock appreciation rights; (c) stock awards; (d) restricted stock; (e) restricted stock units; and (f) performance shares. Eligible participants include officers and employees of the company, members of the Board of Directors, and consultants or other independent contractors. 1,000,000 shares are issuable under the plan. No person shall receive grants of stock options and SARs under the plan that exceed, in the aggregate 200,000 shares of common stock in any one year. The term of each stock option shall be determined by the committee but shall not exceed ten years. Vested stock options may be exercised in whole or part by the holder giving notice to the Company. The holder of the option may provide payment for the exercise price or surrender shares equal to the exercise price.

The Company issued stock options for 632,351 shares of common stock to employees, officers, and directors of the Company through September 30, 2014. Options for 268,455 shares have vested, and the remaining options will have vested over three years. The options were issued with an exercise price between \$8.20 and \$8.71 for those owning more than 10% of the Company's stock and between \$7.46 and \$7.92 for others, which is equal to the estimated market price of the shares on the date of grant valued using Black-Scholes Binomial option pricing model. The expected volatility used in the Black-Scholes model valuation of options issued during the year was 17.03% annualized. The annual volatility rate is based on the standard deviation of the average continuously compounded rate of return of five selected comparable companies over the previous 52 weeks. Forfeiture rate of 15% is based on historical company information and expected future trend. As of September 30, 2014, stock options for 32,750 shares were forfeited.

In September 2014, we entered into a stock option agreement (the Agreement) with a new management employee (the Employee) granting the Employee the right to purchase up to 318,000 of the Company's common stock at an exercise price of \$12.50. The grant of such rights to purchase the Company's common stock was treated as an inducement grant is not included The GWG Holdings Inc. 2013 Stock Incentive plan. The Agreement specifies that, among other things, options to purchase 159,000 shares of the Company's common stock will vest with the Employee ratably on the first, second and third anniversary of the date of the Agreement. The remaining 159,000 options will vest quarterly using a formula based upon the closing price of the Company's common stock on the last business day of such quarter. The maximum number of these remaining options that will vest with the Employee is 53,000 in each successive one year period beginning on the date of the Agreement.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Stock options granted through September 30, 2014:

Date Granted	Exercise Price	Number of Shares	Vesting	Binomial Value	Forfeiture Factor	Compensation Expense
9/5/2013	\$7.52	143,750	Vested	0.36	0.87	\$ 45,023
9/5/2013	\$8.28	25,000	Vested	0.36	0.87	\$ 7,830
9/5/2013	\$7.52	45,838	1 years	0.36	0.85	\$ 14,027
9/5/2013	\$8.28	2,834	1 years	0.36	0.85	\$ 867
9/5/2013	\$7.52	45,833	2 years	0.6	0.72	\$ 19,869
9/5/2013	\$8.28	2,833	2 years	0.6	0.72	\$ 1,228
9/5/2013	\$7.52	45,829	3 years	0.82	0.61	\$ 23,078
9/5/2013	\$8.28	2,833	3 years	0.82	0.61	\$ 1,427
9/30/2013	\$7.52	4,000	Vested	0.66	0.87	\$ 2,297
10/28/2013	\$7.52	6,000	Vested	0.66	0.87	\$ 3,445
10/28/2013	\$7.52	24,000	1 years	0.66	0.85	\$ 13,464
10/28/2013	\$7.52	24,000	2 years	0.92	0.72	\$ 15,953
10/28/2013	\$7.52	18,000	3 years	1.14	0.61	\$ 12,602
11/11/2013	\$7.52	4,167	1 years	0.66	0.85	\$ 2,338
11/11/2013	\$7.52	4,166	2 years	0.92	0.72	\$ 2,769
11/11/2013	\$7.52	4,167	3 years	1.14	0.61	\$ 2,917
12/12/2013	\$7.52	30,000	Vested	0.66	0.87	\$ 17,226
4/1/2014	\$7.46	1,935	Vested	0.468	0.87	\$ 788
4/1/2014	\$7.46	11,007	1 years	1.028	0.85	\$ 9,618
4/1/2014	\$7.46	10,999	2 years	1.24	0.72	\$ 9,854
4/1/2014	\$7.46	10,994	3 years	1.292	0.61	\$ 8,723
4/7/2014	\$7.46	3,334	1 years	1.028	0.85	\$ 2,913
4/7/2014	\$8.20	3,334	1 years	1.028	0.85	\$ 2,913
4/7/2014	\$7.46	3,333	2 years	1.24	0.72	\$ 2,986
4/7/2014	\$8.20	3,333	2 years	1.24	0.72	\$ 2,986
4/7/2014	\$7.46	3,333	3 years	1.292	0.61	\$ 2,645
4/7/2014	\$8.20	3,333	3 years	1.292	0.61	\$ 2,645
4/28/2014	\$7.46	5,000	Vested	0.468	0.87	\$ 2,036
4/28/2014	\$7.46	2,500	1 years	1.028	0.85	\$ 2,185
4/28/2014	\$7.46	2,500	2 years	1.24	0.72	\$ 2,240
4/28/2014	\$7.46	2,500	3 years	1.292	0.61	\$ 1,984
5/27/2014	\$7.46	2,500	Vested	0.468	0.87	\$ 1,018
5/27/2014	\$ 7.46	10,000	1 years	1.028	0.85	\$ 8,738

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

5/27/2014	\$ 7.46	10,000	2 years	1.24	0.72	\$ 8,959	
5/27/2014	\$ 7.46	10,000	3 years	1.292	0.61	\$ 7,934	
6/20/2014	\$ 7.46	3,000	Vested	0.468	0.87	\$ 1,221	
6/20/2014	\$ 7.46	6,000	1 years	1.028	0.85	\$ 5,243	
6/20/2014	\$ 7.46	6,000	2 years	1.24	0.72	\$ 5,375	
6/20/2014	\$ 7.46	3,000	3 years	1.292	0.61	\$ 2,380	
9/2/2014	\$ 7.92	15,000	Vested	2.33	0.85	\$ 29,708	
9/2/2014	\$ 7.92	16,229	1 years	2.383	0.85	\$ 32,873	
9/2/2014	\$8.71	3,334	1 years	1.694	0.85	\$ 4,801	
9/2/2014	\$ 7.92	16,220	2 years	2.564	0.72	\$ 30,068	
9/2/2014	\$8.71	3,334	2 years	1.95	0.72	\$ 4,700	
9/2/2014	\$ 7.92	166	3 years	2.232	0.61	\$ 227	
9/2/2014	\$ 7.92	16,035	3 years	2.804	0.61	\$ 27,607	
9/2/2014	\$8.71	1,666	3 years	2.232	0.61	\$ 2,283	
9/2/2014	\$8.71	1,666	3 years	2.804	0.61	\$ 2,868	
9/3/2014	\$ 7.92	2,515	Vested	2.33	0.85	\$ 4,981	
9/8/2014	\$ 7.92	1,667	1 years	2.383	0.85	\$ 3,377	
9/8/2014	\$ 7.92	1,667	2 years	2.564	0.72	\$ 3,090	
9/8/2014	\$ 7.92	1,667	3 years	2.804	0.61	\$ 2,870	
9/22/2014	\$12.50	13,250	0 years	-2.25	0.85	\$ (25,341)
9/22/2014	\$12.50	13,250	1 years	0.118	0.72	\$ 1,130	
9/22/2014	\$12.50	39,750	1 years	0.118	0.85	\$ 3,987	
9/22/2014	\$12.50	53,000	1 years	2.383	0.85	\$ 107,354	
9/22/2014	\$12.50	13,250	2 years	0.339	0.61	\$ 2,758	
9/22/2014	\$12.50	39,750	2 years	0.339	0.72	\$ 9,743	
9/22/2014	\$12.50	53,000	2 years	2.564	0.72	\$ 98,250	
9/22/2014	\$ 12.50	39,750	3 years	0.585	0.61	\$ 14,281	
9/22/2014	\$ 12.50	53,000	3 years	2.804	0.61	\$ 91,248	
		950,351					

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Outstanding stock options:

	Vested	Un-vested	Total
Balance as of December 31, 2013	195,000	210,250	405,250
Granted during the year	29,950	487,151	517,101
Vested during the year	53,505	(53,505)	-
Forfeited during the year	(10,000)	(22,750)	(32,750)
Balance as of September 30, 2014	268,455	621,146	889,601

Compensation expense related to un-vested options not yet recognized is \$588,000. We expect to recognize this compensation expense over the next 3.50 years. Stock-based compensation cost for the three and nine months ended September 30, 2014 was \$44,000 and \$116,000, respectively.

(13) Net loss per common share

The Company began issuing Series A preferred stock September, 1, 2011, as described in note 9. The Series A preferred stock is anti-dilutive to the net loss per common share calculation at September 30, 2014 and dilutive at September 30, 2013. The Company has also issued warrants to purchase common stock in conjunction with the sale of convertible preferred stock, as discussed in note 9. The warrants are anti-dilutive at September 30, 2014 and 2013, and have not been included in the fully diluted net loss per common share calculation.

(14) Commitments

The Company entered into an office lease with U.S. Bank National Association as the landlord. The lease was effective April 22, 2012 with a term through August 31, 2015. The lease is for 11,695 square feet of office space located at 220 South Sixth Street, Minneapolis, Minnesota. The Company is obligated to pay base rent plus common area maintenance and a share of the building operating costs. Rent expenses under this agreement were \$157,000 and \$149,000 during the nine-month periods ended September 30, 2014 and 2013, respectively, and \$56,000 and \$51,000 during the three-month periods ended September 30, 2014 and 2013, respectively. Minimum lease payments under the

lease agreement effective April 22, 2012 are as follows:

Three months ending December 31, 2014	\$26,000
2015	70,000
Total	\$96,000

(15) Contingencies

Litigation - In the normal course of business, the Company is involved in various legal proceedings. In the opinion of management, any liability resulting from such proceedings would not have a material adverse effect on the Company's financial position, results of operations or cash flows.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Opportunity Finance, LLC, owned by Jon Sabes and Steven Sabes, is subject to litigation clawback claims by the bankruptcy trustee for third-party matters for payments that may have been deemed preference payments. In addition, Jon Sabes and Steven Sabes are subject to litigation clawback claims by the bankruptcy trustee for third-party matters for payments received from Opportunity Finance that may have been deemed preference payments. If the parties are unsuccessful in defending against these claims, their equity ownership in the Company may be sold or transferred to other parties to satisfy such claims. In addition, the Company loaned \$1,000,000 to Opportunity Finance, LLC, and was repaid in full plus interest of \$177,000. This investment amount may also be subject to clawback claims by the bankruptcy court.

(16) Guarantees of secured debentures

GWG Holdings has registered with the SEC the offer and sale \$250,000,000 of secured debentures as described in note 8. The secured debentures are secured by the assets of GWG Holdings as described in note 8 and a pledge of all the common stock by the largest shareholders. Obligations under the debentures are guaranteed by GWG Life. This guarantee involves the grant of a security interest in all the assets of GWG Life. The payment of principal and interest on the secured debentures is fully and unconditionally guaranteed by GWG Life. Substantially all of the Company's life insurance policies are held by DLP II and the Trust. The policies held by DLP II are not collateral for the debenture obligations as such policies are collateral for the credit facility.

The consolidating financial statements are presented in lieu of separate financial statements and other related disclosures of the subsidiary guarantors and issuer because management does not believe that separate financial statements and related disclosures would be material to investors. There are currently no significant restrictions on the ability of GWG Holdings or GWG Life, the guarantor subsidiary, to obtain funds from its subsidiaries by dividend or loan, except as follows. DLP II is a borrower under a credit agreement with Autobahn, with DZ Bank AG as agent, as described in note 6. The significant majority of insurance policies owned by the Company are subject to a collateral arrangement with DZ Bank AG described in note 6. Under this arrangement, collection and escrow accounts are used to fund premiums of the insurance policies and to pay interest and other charges under the revolving credit facility. DZ Bank AG and Autobahn must authorize all disbursements from these accounts, including any distributions to GWG Life. Distributions are limited to an amount that would result in the borrowers (DLP II, GWG Life and GWG Holdings) realizing an annualized rate of return on the equity funded amount for such assets of not more than 18%, as determined by DZ Bank AG. After such amount is reached, the credit agreement requires that excess funds be used for repayments of borrowings before any additional distributions may be made.

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

The following represents consolidating financial information as of September 30, 2014 and December 31, 2013, with respect to the financial position, and for the three and nine months ended September 30, 2014 and 2013 with respect to results of operations and cash flows of GWG Holdings and its subsidiaries. The parent column presents the financial information of GWG Holdings, the primary obligor of the secured debentures. The guarantor subsidiary column presents the financial information of GWG Life, the guarantor subsidiary of the secured debentures, presenting its investment in DLP II and Trust under the equity method. The non-guarantor subsidiaries column presents the financial information of all non-guarantor subsidiaries including DLP II and Trust.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Condensed Consolidating Balance Sheets

September 30, 2014	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ASSETS Cash and cash equivalents Restricted cash Investment in life settlements, at fair value Other assets Investment in subsidiaries	\$27,051,595 - - 1,336,301 171,512,960	\$2,460,394 - - 1,753,198 198,872,078	\$- 2,144,734 276,381,979 364,475 -	\$- - - (370,385,038)	\$29,511,989 2,144,734 276,381,979 3,453,974
TOTAL ASSETS	\$199,900,856	\$203,085,670	\$278,891,188	\$(370,385,038)	\$311,492,676
LIABILITIES & STOCKHOLDE LIABILITIES	RS' EQUITY (DEFICIT)			
Revolving credit facility Series I Secured notes payable Renewable Secured Debentures Interest payable Accounts payable and other accrued expenses	\$- - 169,186,917 5,903,351 1,044,275	\$- 27,701,842 - 3,354,424 516,444	\$79,000,000 - 510,443 508,667	\$- - - -	\$79,000,000 27,701,842 169,186,917 9,768,218 2,069,386
Deferred taxes TOTAL LIABILITIES	3,545,504 179,680,047	- 31,572,710	- 80,019,110	-	3,545,504 291,271,867
STOCKHOLDERS' EQUITY (DEFICIT)					
Member capital Convertible, redeemable preferred stock	- 20,217,836	171,512,960 -	198,872,078 -	(370,385,038)	- 20,217,836
Common stock Additional paid-in capital Accumulated deficit	5,870 16,323,738 (16,326,635)		- -	-	5,870 16,323,738 (16,326,635)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	20,220,809	171,512,960	198,872,078	(370,385,038)	20,220,809

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$199,900,856 \$203,085,670 \$278,891,188 \$(370,385,038) \$311,492,676 (DEFICIT)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Condensed Consolidating Balance Sheets (continued)

December 31, 2013	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ASSETS Cash and cash equivalents Restricted cash Investment in life settlements, at fair value Other assets Investment in subsidiaries	\$32,711,636 - - 381,883 129,839,241	\$738,157 (1,420,000) - 484,510 159,798,490	\$- 4,412,970 234,672,794 558,526 -	\$- - - (289,637,731)	\$33,449,793 5,832,970 234,672,794 1,424,919
TOTAL ASSETS	\$162,932,760	\$162,441,157	\$239,644,290	\$(289,637,731)	\$275,380,476
LIABILITIES & STOCKHOLDERS LIABILITIES					
Revolving credit facility	\$-	\$-	\$79,000,000	\$-	\$79,000,000
Series I Secured notes payable Renewable Secured Debentures Interest payable	- 131,646,062 3,806,820	29,275,202 - 3,065,465	- 337,123	-	29,275,202 131,646,062 7,209,408
Accounts payable and other accrued expenses	574,026	261,249	508,677	-	1,343,952
Deferred taxes, net TOTAL LIABILITIES	7,675,174 143,702,082	- 32,601,916	- 79,845,800	-	7,675,174 256,149,798
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	24,722,693	-	-	-	24,722,693
STOCKHOLDERS' EQUITY (DEFICIT)					
Member capital	-	129,839,241	159,798,490	(289,637,731)	
Common stock Additional paid-in capital	9,124 2,937,438	-	-	-	9,124 2,937,438
Accumulated deficit	(8,438,577)	-	-	-	(8,438,577)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	(5,492,015)		159,798,490	(289,637,731)	

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

\$162,932,760 \$162,441,157 \$239,644,290 \$(289,637,731) \$275,380,476

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Condensed Consolidating Statements of Operations

For the nine months ended September 30, 2014 REVENUE	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
Contract servicing fees Gain on life settlements, net Interest and other income	\$- - 17,501	\$1,462,376 - 229,348	\$ - 16,119,517 5,218	\$(1,462,376) - (228,092)	16,119,517
TOTAL REVENUE	17,501	1,691,724	16,124,735	(1,690,468)	16,143,492
EXPENSES Origination and servicing fees Employee compensation and benefits Legal and professional fees Interest expense Other expenses	- 1,992,554 1,476,213 13,371,300 1,937,674	- 1,531,720 141,470 2,334,097 1,299,666	1,462,376 - 10,086 4,025,930 268,602	(1,462,376) - - (228,092)	3,524,274 1,627,769 19,731,327
TOTAL EXPENSES	18,777,741	5,306,953	5,766,994	(1,690,468)	28,161,220
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	(18,760,240)	(3,615,229)	10,357,741	-	(12,017,728)
EQUITY IN INCOME OF SUBSIDIARY	6,742,512	10,357,741	-	(17,100,253)	-
NET INCOME (LOSS) BEFORE INCOME TAXES	(12,017,728)	6,742,512	10,357,741	(17,100,253)	(12,017,728)
INCOME TAX BENEFIT NET INCOME (LOSS)	(4,129,670) \$(7,888,058)		- \$ 10,357,741	\$(17,100,253)	(4,129,670) \$(7,888,058)
For the nine months ended September 30, 2013 REVENUE	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries \$ -	Eliminations	Consolidated
Contract servicing fees Gain on life settlements, net	\$- -	\$2,818,309	\$- 21,511,182	\$(2,818,309) -) \$- 21,511,182

Edgar Filing: GWG Holdings, Inc Form 10-Q							
Interest and other income	3,324,771	1,956,863	69,943	(1,819,655)	3,531,922		
TOTAL REVENUE	3,324,771	4,775,172	21,581,125	(4,637,964)	25,043,104		
EXPENSES Origination and servicing fees Employee compensation and benefits Legal and professional fees Interest expense Other expenses	- 2,801,017 766,785 8,249,849 1,752,769	- 1,300,485 367,396 2,763,918 1,164,968	2,818,309 - - 3,932,717 1,857,155	(2,818,309) - - (1,819,655)	- 4,101,502 1,134,181 14,946,484 2,955,237		
TOTAL EXPENSES	13,570,420	5,596,767	8,608,181	(4,637,964)	23,137,404		
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	(10,245,649)	(821,595)	12,972,944	-	1,905,700		
EQUITY IN INCOME OF SUBSIDIARY	12,151,349	13,021,463	-	(25,172,812)	-		
NET INCOME BEFORE INCOME TAXES	1,905,700	12,199,868	12,972,944	(25,172,812)	1,905,700		
INCOME TAX EXPENSE NET INCOME	1,710,826 \$194,874	- \$12,199,868	- \$ 12,972,944	- \$(25,172,812)	1,710,826 \$194,874		

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Condensed Consolidating Statements of Operations (continued)

For the three months ended September 30, 2014 REVENUE	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
Contract servicing fees	\$ -	\$153,470	\$ -	\$(153,470)	\$ -
Gain on life settlements, net	φ-	\$155,470	5,118,423	\$(155,770)	5,118,423
Interest and other income	-	-	5,118,425	-	10,229
Interest and other income	4,572	59,372	5,150	(58,871)	10,229
TOTAL REVENUE	4,572	212,842	5,123,579	(212,341)	5,128,652
EXPENSES					
Origination and servicing fees	-	-	153,470	(153,470)	-
Employee compensation and benefits	737,475	639,235	-	-	1,376,710
Legal and professional fees	734,024	16,020	10,086	-	760,130
Interest expense	4,679,311	761,828	1,355,597	-	6,796,736
Other expenses	850,122	587,745	74,371	(58,871)	1,453,367
	000,122	001,110	/ 1,5 / 1	(00,071)	1,100,007
TOTAL EXPENSES	7,000,932	2,004,828	1,593,524	(212,341)	10,386,943
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	(6,996,360)	(1,791,986)	3,530,055	-	(5,258,291)
EQUITY IN INCOME OF SUBSIDIARY	1,738,069	3,530,055	-	(5,268,124)	-
NET INCOME (LOSS) BEFORE INCOME TAXES	(5,258,291)	1,738,069	3,530,055	(5,268,124)	(5,258,291)
INCOME TAX BENEFIT NET INCOME (LOSS)	(1,858,100) \$(3,400,191)		- \$ 3,530,055	\$(5,268,124)	(1,858,100) \$(3,400,191)

For the three months ended September 30, 2013	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
REVENUE					
Contract servicing fees	\$-	\$1,004,107	\$ -	\$(1,004,107)	\$ -
Gain on life settlements, net	-	-	5,437,580	-	5,437,580

Edgar Filing: GWG Holdings, Inc Form 10-Q							
Interest and other income	57,317	979,007	32,322	(978,719)	89,927		
TOTAL REVENUE	57,317	1,983,114	5,469,902	(1,982,826)	5,527,507		
EXPENSES Origination and servicing fees Employee compensation and benefits Legal and professional fees Interest expense Other expenses	- 587,961 164,334 3,273,250 399,634	- 512,198 256,540 914,056 342,932	1,004,107 - - 1,350,020 991,219	(1,004,107) - - (978,719)	- 1,100,159 420,874 5,537,326 755,066		
TOTAL EXPENSES	4,425,179	2,025,726	3,345,346	(1,982,826)	7,813,425		
INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES	(4,367,862)	(42,612)	2,124,556	-	(2,285,918)		
EQUITY IN INCOME OF SUBSIDIARY	2,081,944	2,124,556	-	(4,206,500)	-		
NET INCOME (LOSS) BEFORE INCOME TAXES	(2,285,918)	2,081,944	2,124,556	(4,206,500)	(2,285,918)		
INCOME TAX EXPENSE (BENEFIT) NET INCOME (LOSS)	(656,968) \$(1,628,950)	- \$2,081,944	- \$ 2,124,556	- \$(4,206,500)	(656,968) \$(1,628,950)		

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Condensed Consolidating Statements of Cash Flows

For the nine months ended September 30, 2014 CASH FLOWS FROM OPERATING	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to cash flows from operating activities:	\$(7,888,058)	\$6,742,512	\$ 10,357,741	\$(17,100,253)	\$(7,888,058)
(Equity) loss of subsidiaries	(6,742,512)	(10,357,741)		17,100,253	-
Life settlements – change in fair value Amortization of deferred financing	-	-	(30,973,250)	-	(30,973,250)
and issuance costs	2,125,269	427,187	18,425	-	2,570,881
Deferred income taxes	(4,129,670)	-	-		(4,129,670)
Preferred stock issued for dividends (Increase) in operating assets:	575,513	-	-	-	575,513
Other assets	(35,758,660)	(29,984,534)	-	63,647,054	(2,096,140)
Increase in operating liabilities:	· · · · ·				
Accounts payable and other accrued expenses	2,893,814	591,534	173,311	-	3,658,659
NET CASH FLOWS USED IN OPERATING ACTIVITIES	(48,924,304)	(32,581,042)	(20,423,773)	63,647,054	(38,282,065)
CASH FLOWS FROM INVESTING ACTIVITIES					
Investment in life settlements	-	-	(11,559,435)	-	(11,559,435)
Proceeds from settlement of life	-	-	999,125	-	999,125
settlements NET CASH FLOWS USED IN INVESTING ACTIVITIES	-	-	(10,560,310)	-	(10,560,310)
CASH FLOWS FROM FINANCING ACTIVITIES					
Payments for redemption of Series I Secured notes payable	-	(2,047,928)	-	-	(2,047,928)
Proceeds from issuance of debentures	48,516,296 (13,816,794)	-	-	-	48,516,296 (13,816,794)

Payments for issuance costs and					
redemption of Renewable					
Secured Debentures					
Proceeds from restricted cash	-	1,420,000	2,268,236	-	3,688,236
Proceeds from sale of common stock	9,030,000	-	-	-	9,030,000
Payments for redemption of preferred stock	(465,239)	-	-	-	(465,239)
Issuance of member capital	-	34,931,207	28,715,847	(63,647,054)	-
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	43,264,263	34,303,279	30,984,083	(63,647,054)	44,904,571
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(5,666,041)	1,722,237	-	-	(3,937,804)
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	32,711,636	738,157	-	-	33,449,793
END OF PERIOD	\$27,051,595	\$2,460,394	\$ -	\$-	\$29,511,989

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Consolidating Statements of Cash Flows (continued)

For the nine months ended September 30, 2013 CASH FLOWS FROM OPERATING	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ACTIVITIES Net income Adjustments to reconcile net income to cash:	\$194,874	\$12,199,868	\$12,972,944	\$(25,172,812)	\$194,874
Equity income of subsidiaries (Gain) loss on life settlements	1,099,118	1,256,636	- (25,904,240)	(2,355,754)	- (25,904,240)
Amortization of deferred financing and issuance costs	1,368,147	599,431	1,089,215	-	3,056,793
Deferred income taxes Preferred stock issued for dividends (Increase) decrease in operating	1,710,826 443,486	-	:	-	1,710,826 443,486
assets: Other assets Increase (decrease) in operating	(49,033,785)	(46,664,803)	(2,830,802)	95,347,929	(3,181,461)
liabilities: Accounts payable and other accrued expenses	1,914,318	614,418	(359,862)	-	2,168,874
NET CASH FLOWS USED IN OPERATING ACTIVITIES	(42,303,016)	(31,994,450)	(15,032,745)	67,819,363	(21,510,848)
CASH FLOWS FROM INVESTING ACTIVITIES					
Investment in life settlements	-	-	(26,916,790)	-	(26,916,790)
Proceeds from settlement of life settlements	-	-	4,203,895	-	4,203,895
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-	-	(22,712,895)	-	(22,712,895)
CASH FLOWS FROM FINANCING ACTIVITIES					
Net proceeds from revolving credit facility	-	-	8,000,000	-	8,000,000
raemty	-	(6,242,586)	-	-	(6,242,586)

Payments for redemption of Series I Secured notes payable					
Proceeds from issuance of debentures	62,056,755	-	-	-	62,056,755
Payments from redemption and issuance of debentures	(9,642,129)	-	-	-	(9,642,129)
Proceeds (payments) from restricted cash	-	1,094,415	(2,510,973) –	(1,416,558)
Issuance of member capital Repurchase of common stock	- (3,252,400)	35,562,750	32,256,613	(67,819,363)	- (3,252,400)
Payments for redemption of preferred stock	(347,089)	-	-		(347,089)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	48,815,137	30,414,579	37,745,640	(67,819,363)	49,155,993
NET INCREASE IN CASH AND CASH EQUIVALENTS	6,512,121	(1,579,871)	-	-	4,932,250
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	25,035,579	2,461,465	-	-	27,497,044
END OF PERIOD	\$31,547,700	\$881,594	\$ -	\$-	\$32,429,294

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Consolidating Statements of Cash Flows (continued)

For the three months ended September 30, 2014 CASH FLOWS FROM OPERATING	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ACTIVITIES Net income (loss) Adjustments to reconcile net loss to cash:	\$(3,400,191)	\$1,738,069	\$ 3,530,055	\$(5,268,124)	\$(3,400,191)
(Equity) loss of subsidiaries Life settlements – change in fair value	(1,738,069)	(3,530,055)	- (8,761,912)	5,268,124	- (8,761,912)
Amortization of deferred financing and issuance costs	397,659	126,083	339,475	-	863,217
Deferred income taxes Preferred stock issued for dividends (Increase) in operating assets:	(1,858,100) 186,182	-	-	-	(1,858,100) 186,182
Other assets Increase in operating liabilities:	(9,136,310)	(5,329,716)	300,000	13,318,805	(847,221)
Accounts payable and other accrued expenses	922,271	289,132	(720,907)	-	490,496
NET CASH FLOWS USED IN OPERATING ACTIVITIES	(14,626,558)	(6,706,487)	(5,313,289)	13,318,805	(13,327,529)
CASH FLOWS FROM INVESTING					
ACTIVITIES Investment in life settlements	-	-	(680,000)	-	(680,000)
Proceeds from settlement of life settlements	-	-	930,625	-	930,625
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-	-	250,625	-	250,625
CASH FLOWS FROM FINANCING ACTIVITIES					
Payments for redemption of Series I Secured notes payable	-	(509,004)	-	-	(509,004)
Proceeds from issuance of debentures Payments for issuance costs and redemption of Renewable	15,281,809 (4,494,383)	-	-	-	15,281,809 (4,494,383)

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

Secured Debentures Proceeds from restricted cash Proceeds from sale of common stock Payments for redemption of preferred stock Issuance of member capital NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	- 9,030,000 (445,183) - 19,372,243	565,000 - - 8,356,840 8,412,836	100,699 - - 4,961,965 5,062,664	- - (13,318,805) (13,318,805)	665,699 9,030,000 (445,183) - 19,528,938
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	4,745,685	1,706,349	-	-	6,452,034
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	22,305,910	754,045	-	-	23,059,955
END OF PERIOD	\$27,051,595	\$2,460,394	\$ -	\$-	\$29,511,989

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Consolidating Statements of Cash Flows (continued)

For the three months ended September 30, 2013 CASH FLOWS FROM OPERATING	Parent	Guarantor Subsidiary	Non-Guarantor Subsidiaries	Eliminations	Consolidated
ACTIVITIES Net income Adjustments to reconcile net income to cash:	\$(1,628,950)	\$2,081,944	\$2,124,556	\$(4,206,500)	\$(1,628,950)
Equity income of subsidiaries	2,081,944	2,124,556	-	(4,206,500)	-
(Gain) loss on life settlements Amortization of deferred financing	-	-	(6,960,335)	-	(6,960,335)
and issuance costs	630,188	165,000	330,725		1,125,913
Deferred income taxes	(655,968)	-	-		(655,968)
Preferred stock issued for dividends (Increase) decrease in operating	185,231	-	-		185,231
assets:					
Other assets	(21,755,694)	(22,309,588)	500,000	43,997,953	432,671
Increase (decrease) in operating liabilities:					
Accounts payable and other accrued					
expenses	425,529	494,915	(450,049)	-	470,395
NET CASH FLOWS USED IN OPERATING ACTIVITIES	(20,717,720)	(17,443,173)	(4,455,103)	35,584,953	(7,031,043)
CASH FLOWS FROM INVESTING ACTIVITIES					
Investment in life settlements	-	-	(14,030,797)	-	(14,030,797)
Proceeds from settlement of life settlements	-	-	1,331,743	-	1,331,743
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-	-	(12,699,054)	1	(12,699,054)
CASH FLOWS FROM FINANCING ACTIVITIES					
Payments for redemption of Series I	_	(2,311,710)	_		(2,311,710)
Secured notes payable	10 617 004	(2,511,710)			
Proceeds from issuance of debentures	19,617,094	-	-		19,617,094

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

Payments from redemption and issuance of debentures	(4,305,558)	-	-		(4,305,558)
Proceeds (payments) from restricted cash	-	1,847,215	(892,998)	954,217
Issuance of member capital	-	17,537,798	18,047,155	(35,584,953)	-
Payments for redemption of preferred stock	(35,285)	-	-		(35,285)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	15,276,251	17,073,303	17,154,157	(35,584,953)	13,918,758
NET INCREASE IN CASH AND CASH EQUIVALENTS	(5,441,469)	(369,870)	-	-	(5,811,339)
CASH AND CASH EQUIVALENTS BEGINNING OF PERIOD	36,989,169	1,251,464	-	-	38,240,633
END OF PERIOD	\$31,547,700	\$881,594	\$ -	\$-	\$32,429,294

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(17) Concentrations

GWG purchases life insurance policies written by life insurance companies having investment grade ratings by independent rating agencies. As a result there may be certain concentrations of contracts with life insurance companies. The following summarizes the face value of insurance contracts with specific life insurance companies exceeding 10% of the total face value held by the Company.

	September	December
	30,	31,
	2014	2013
Life insurance company	%	%
Company A	15.66	16.58
Company B	11.35	11.34

The following summarizes the number of insurance contracts held in specific states exceeding 10% of the total face value held by the Company:

	September 30,	31,
State of residence	2014 %	2013 %
California	28.72	28.14
Florida	17.65	15.59
New York	10.03	10.65

ITEM MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATIONS.

You should read the following discussion in conjunction with the consolidated financial statements and accompanying notes and the information contained in other sections of this report. This discussion and analysis is based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. The statements in this discussion and analysis and elsewhere in this report, concerning expectations regarding our future performance, liquidity and capital resources, as well as other non-historical statements, are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties. Our actual results could differ materially from those suggested or implied by any forward-looking statements.

Overview

We are engaged in providing financial services in the emerging secondary market for life insurance settlements. Our financial service offerings are targeted towards consumers owning life insurance who can benefit from the actuarial value of their life insurance policy. To date, our primary financial service has been to offer consumers the ability to sell their policy for cash. In addition, we have offered investors the opportunity to participate in our business through a series of debt offerings. We are in the process of expanding the services we offer consumers who own life insurance by offering them options such as to retain a portion of their policy benefits or to exchange their life insurance for a more desirable asset. All of the services we offer are based upon acquiring or otherwise financing, life insurance policy benefits from consumers in the secondary market at a discount to the face value of the insurance benefit. Once we purchase or finance a policy benefit. We seek to hold the policies to maturity, in order to ultimately collect the policy's benefit upon the insured's mortality. Our strategy is to build a profitable (purchased at discounts sufficient to provide a positive return on investment) and large (greater than 300 lives) portfolio of policies that are well diversified in terms of insurance carriers and the mortality profiles of insureds. We believe that diversification among insurers, mortality profiles, and medical conditions will lower our overall risk exposure, and that a larger number of policies (diversification in overall number) will provide our portfolio with greater actuarial stability.

In the first nine months of 2014, we recognized \$2,301,000 of revenue from the receipt of \$3,300,000 in policy benefits. In addition, we recognized revenue from the change in fair value of our life insurance policies, net of premiums and carrying costs, of \$13,819,000. In the same period, our interest expense, including amortization of the deferred financing costs and preferred stock dividends, was \$19,731,000, and selling, general and administrative expenses were \$8,430,000. In the first nine months of 2014, we recognized income tax benefit of \$4,130,000. Our net loss for the nine months ended September 30, 2014 was \$7,888,000.

Critical Accounting Policies

Critical Accounting Estimates

The preparation of our consolidated financial statements in accordance with the Generally Accepted Accounting Principles (GAAP) requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our judgments, estimates, and assumptions on historical experience and on various other factors believed to be reasonable under the circumstances. Actual results could differ materially from these estimates. We evaluate our judgments, estimates and assumptions on a regular basis and make changes accordingly. We believe that the judgments, estimates and assumptions involved in the accounting for the valuation of investments in life insurance policies have the greatest potential impact on our consolidated financial statements and accordingly believe these to be our critical accounting estimates. Below we discuss the critical accounting policies associated with these estimates as well as certain other critical accounting policies.

Ownership of Life Insurance Policies—Fair Value Option

Our primary business involves the purchasing and financing of life insurance policies. As such, we account for the purchase of life insurance policies in accordance with ASC 325-30, *Investments in Insurance Contracts*, which requires us to use either the investment method or the fair value method. We have elected to account for these life insurance policies as investments using the fair value method.

We initially record our purchase of life insurance policies at the transaction price, which is the amount paid for the policy, inclusive of all fees and costs associated with the acquisition. The fair value of our investment in the portfolio of insurance policies is evaluated at the end of each reporting period. Changes in the fair value of the portfolio of life insurance policies are based on periodic evaluations and are recorded as changes in fair value of life settlements in our consolidated and combined statement of operations. The fair value is determined as the net present value of the life insurance portfolio's future expected cash flows that incorporates current life expectancy estimates and discount rate assumptions.

In addition to reporting our results of operations and financial condition based on the fair value of our life insurance policies as required by GAAP, management also makes calculations based on the weighted average expected internal rate of return of the policies. See "Non-GAAP Financial Measures" below.

Valuation of Insurance Policies

Unobservable inputs, as discussed below, are a critical component of our estimate for the fair value of our investments in life insurance policies. We currently use a probabilistic method of estimating and valuing the projected cash flows of our portfolio of life insurance policies, which we believe to be the preferred and most prevalent valuation method in the industry. In this regard, the most significant assumptions we make are the life expectancy estimates of the insureds and the discount rate applied to the projected cash flows to be derived from our portfolio.

In determining life expectancy estimates, we generally use actuarial medical reviews from independent medical underwriters. These medical underwriters summarize the health of the insured by reviewing historical and current medical records. The medical underwriters evaluate the health condition of the insured in order to produce an estimate of the insured's mortality—a life expectancy report. In the case of a small face policy (\$1 million face value or less), we may use one life expectancy report or estimate life expectancy based on a modified methodology which does not use actuarial medical reviews from independent medical underwriters. The life expectancy estimate represents a range of probabilities for the insured's mortality against a group of cohorts with the same age, sex and smoking status. These mortality probabilities represent a mathematical curve known as a mortality curve, which is then used to generate a series of expected cash flows from the life insurance policy over the expected lifespan of the insured. A discount rate is used to calculate the net present value of the expected cash flows. The discount rate represents the internal rate of return we expect to earn on investments in a policy or in the portfolio as a whole at the stated fair value. The discount rate used to calculate fair value of our portfolio incorporates the guidance provided by ASC 820, Fair Value Measurements and Disclosures. Many of our current underwriting review processes, including our policy of obtaining actuarial medical reviews from independent medical underwriters as described above, are undertaken in satisfaction of obligations under our revolving credit facility. As a result, we may in the future modify our underwriting review processes if permitted under our borrowing arrangements.

The table below provides the discount rate used to estimate the fair value of the life insurance policies for the period ending:

September	December
30, 2014	31, 2013
11.56%	11.69%

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

The change in the discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance policies, discount rates observed in the life insurance secondary market, market interest rates, the credit exposure to the issuing insurance companies and our estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance policies. The discount rate to arrive at the fair value of our portfolio assumes an orderly and arms-length transaction (i.e., a non-distressed transaction in which neither seller nor buyer is compelled to engage in the transaction).

We engaged a third party, Model Actuarial Pricing Systems (MAPS), to prepare a third-party valuation of our life settlement portfolio. MAPS owns and maintains the portfolio pricing software we use. MAPS processed policy data, future premium data, life expectancy estimate data, and other actuarial information we supply to calculate a net present value for our portfolio using the specified discount rate of 11.56%. MAPS independently calculated the net present value of our portfolio of 289 policies to be \$276,381,979, which is the same fair value estimate we used on the balance sheet as of September 30, 2014, and furnished us with a letter documenting its calculation. A copy of such letter is filed as Exhibit 99.1 to this report.

JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or JOBS Act, was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 for complying with new or revised accounting standards. This means that an "emerging growth company" can make an election to delay the adoption of certain accounting standards until those standards would apply to private companies. We have elected to delay such adoption of new or revised accounting standards and, as a result, we may not comply with new or revised accounting standards at the same time as other public reporting companies that are not "emerging growth companies." This exemption will apply for a period of five years following our first sale of common equity securities under an effective registration statement or until we no longer qualify as an "emerging growth company" as defined under the JOBS Act, whichever is earlier.

Deferred Income Taxes

ASC 740, *Income Taxes*, requires us to recognize deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established for any portion of deferred tax assets that is not considered more likely than not to be realized.

We have provided a valuation allowance against the deferred tax asset related to a note receivable because we believe that, when realized for tax purposes, it will result in a capital loss that will not be utilized because we have no expectation of generating a capital gain within the applicable carryforward period. Therefore, we do not believe that it is more likely than not that the deferred tax asset will be realized.

We have also provided a valuation allowance against the deferred tax asset related to a tax basis capital loss generated with respect to its settlement and subsequent disposal of our investment in Athena Structured Funds PLC (see "Notes to Consolidated Financial Statements" Note 10). As we have no expectation of generating capital gains within the applicable carry-forward period, we do not believe that it is more likely than not that the deferred asset will be realized.

A valuation allowance is required to be recognized to reduce deferred tax assets to an amount that is more likely than not to be realized. Realization of deferred tax assets depends upon having sufficient past or future taxable income in periods to which the deductible temporary differences are expected to be recovered or within any applicable carryback or carryforward periods. We believe that it is more likely than not that we will be able to realize all of our deferred tax assets other than that which is expected to result in a capital loss.

Deferred Financing and Issuance Costs

Financing costs incurred to obtain financing under the revolving credit facility have been capitalized and are amortized using the straight-line method over the term of the revolving credit facility. The Series I Secured note obligations are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Renewable Secured Debentures are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A preferred stock is reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which are amortized using the interest method as interest expense over the three-year redemption period.

Risk Relating to Forward-Looking Statements

Certain matters discussed in this section of this report, and elsewhere in this report, are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, these forward-looking statements are subject to risks, uncertainties and assumptions about our operations and the investments we make, including, among other things, the following:

changes in the secondary market for life insurance; our limited operating history; the valuation of assets reflected on our financial statements; the reliability of our life expectancy estimates; the reliability of assumptions underlying our actuarial models; our reliance of debt financing; risks relating to the validity and enforceability of the life insurance policies we purchase; our reliance on information provided and obtained by third parties; federal and state regulatory matters; additional expenses, not reflected in our operating history, related to being a public reporting company; competition in the secondary life insurance market; the relative illiquidity of life insurance policies; life insurance company credit exposure; economic outlook; performance of our investments in life insurance policies; financing requirements; litigation risks; and restrictive covenants contained in borrowing agreements.

Forward-looking statements can generally be identified by the use of words like "believes," "could," "possibly," "probably," "anticipates," "estimates," "projects," "expects," "may," "will," "should," "seek," "intend," "plan," "expect" or "consider," or these expressions or other variations, or by discussions of strategy that involve risks and uncertainties. All forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual transactions, results, performance or achievements to be materially different from any future transactions, results, performance or implied by such forward-looking statements.

Principal Revenue and Expense Items

We earn revenues from three primary sources as described below.

Policy Benefits Realized. We recognize the difference between the insurance benefits and carrying values of the policy when an insured event has occurred and we determine that settlement and ultimate collection of the insurance benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. We generally collect the face value of the life insurance policy from the insurance company within 45 days of the insured's mortality.

Change in Fair Value of Life Insurance Policies. We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, *Investments in Life Insurance Contracts.* Accordingly, we value our investments in our portfolio of life insurance policies each reporting period in accordance with the fair value principles discussed herein, which includes the expected payment of premiums for future periods.

Sale of a Life Insurance Policy or a Portfolio of Life Insurance Policies. In an event of a sale of a policy, we recognize gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale.

Our main components of expense are summarized below.

Selling, General and Administrative Expenses. We recognize and record expenses incurred in the operations of the purchasing and servicing of life insurance policies. These expenses include professional fees, salaries, and sales and marketing expenditures.

Interest Expense. We recognize and record interest expenses associated with the costs of financing our life insurance portfolio for the current period. These expenses include interest paid to our senior lender under our revolving credit facility, as well as all interest paid on our debentures and other outstanding indebtedness such as our subsidiary secured notes and dividends on convertible, redeemable preferred stock. When we issue long-term indebtedness, we amortize the issuance costs associated with such indebtedness over the outstanding term of the financing, and classify it as interest expense.

Results of Operations — Three and Nine Months Ended September 30, 2014 Compared to the Same Periods in 2013

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

The following is our analysis of the results of operations for the periods indicated below. This analysis should be read in conjunction with our consolidated financial statements and related notes.

Revenue. Revenue recognized from the receipt of policy benefits was \$2,070,000 and \$2,301,000 during the three and nine months ended September 30, 2014, respectively. Revenue recognized from the receipt of policy benefits was \$3,668,000 and \$11,396,000 during the three and nine months ended September 30, 2013, respectively. Revenue recognized from the change in fair value of our life insurance policies, net of premiums and carrying costs, was \$3,049,000 and \$13,819,000 for the three and nine months ended September 30, 2014, respectively and \$1,769,000 and \$10,115,000 for the three and nine months ended September 30, 2013, respectively. During the nine-month period ended September 30, 2013, we purchased a higher volume of life insurance policies than we did during the same period in 2014. The change in fair value related to new policies acquired during the three and nine month periods ended September 30, 2014 was \$964,000 and \$7,523,000 respectively, and \$6,732,000 and \$19,762,000 for those acquired during the three-month and nine-month periods ended September 30, 2013, respectively. In each case, the increases in fair value were due to changes in the discount rates we use to calculate the net present value of cash flows expected from our portfolio of life insurance policies, change in fair value of policies acquired during the period, and aging of the policies. The discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance policies, discount rates observed in the life insurance secondary market, market interest rates, the credit exposure to the insurance company that issued the life insurance policy and management's estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance policies. The discount rate used to estimate the fair value of the life insurance policies we own was 11.56% as of September 30, 2014, compared to 11.77% as of September 30, 2013. The decrease in discount rate was due to changes in a variety of factors in our fair value methodology. The carrying value of policies acquired during each quarterly reporting period are adjusted to their current fair value using the fair value discount rate applied to the portfolio as of that reporting date.

Expenses. Interest expense, including amortization of the deferred financing costs as well as preferred stock dividends, were \$6,797,000 and \$19,731,000 during the three and nine months ended September 30, 2014, compared to \$5,537,000 and \$14,946,000 during the same periods of 2013, increases of \$1,260,000 and \$4,785,000, respectively. The increase was due to the increased debt outstanding that increased from \$225,362,000 at September 30, 2013 to \$280,438,000 at September 30, 2014, principally to fund acquisition of policies, make premium payments, pay interest and principal on the outstanding debt, and fund operating expenses. Selling, general, and administrative expenses were \$3,590,000 and \$8,430,000 during the three and nine months ended September 30, 2014, compared to \$2,276,000 and \$8,191,000 during the same periods of 2013, an increase of \$1,314,000 and \$239,000, respectively. The third quarter of 2014 over the same quarter of 2013 selling, general and administrative expenses increase was due to \$277,000 increase in legal and professional fees, and \$698,000 increase in marketing, recruiting and other fees.

Income Tax Expense. For the three and nine months ended September 30, 2014, we had a loss of \$3,400,000 and \$7,888,000 before income taxes and recorded income tax benefit of \$1,858,000 and \$4,130,000, respectively, or 35.3% and 34.4%, respectively. In the same periods of 2013, we recorded income tax benefit of \$657,000 (or 28.7% of income before taxes) and income tax expense of \$1,711,000 (or 89.8% of income before taxes). The primary differences between our effective tax rate and the statutory federal rate are the accrual of preferred stock dividend expense, state taxes, and other non-deductible expenses. Excluding the impact of the dividends and other permanent differences, the effective tax rate for the three and nine months ended September 30, 2014 and 2013 would have been 43.8% and 40.5%, respectively.

The following table provides a reconciliation of our income tax expense at the statutory federal tax rate to our actual income tax expense:

Six months ended:	Three Months Ended September 30, 2014		Nine Months Ended September 30, 2014		Three Month Ended September 3 2013		Nine Months Ended September 30, 2013	
Statutory federal income tax	\$(1,788,000)	34.0%	\$(4,086,000)	34.0%	\$777,000	34.0%	\$(648,000)	34.0%
State income taxes, net of federal benefit	(297,000)	5.6 %	(649,000)	5.4 %	105,000	4.6 %	(251,000)	13.2%
Series A preferred stock dividends	216,000	(4.1)%	650,000	(5.4)%	(215,000)	(9.4)%	(645,000)	33.9%
Other permanent differences	11,000	(0.2)%	(45,000)	0.4 %	(10,000)	(0.5)%	(167,000)	8.7 %
Total income tax expense	\$(1,858,000)	35.3%	(4,130,000)	34.4%	\$657,000	28.7%	(1,711,000)	89.8%

The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance policies and revenue recognition with respect to the mark-to-market of life insurance portfolio.

Liquidity and Capital Resources

We finance our business through a combination of policy benefit revenues, origination fees, equity offerings, debt offerings, and a credit facility. We have used our debt offerings and credit facility primarily for policy acquisition, policy servicing and portfolio related financing expenditures. We charge an intercompany origination fee in the amount of one to four percent of the face value of a life insurance policy's benefit when we acquire the related life insurance policy. The origination fee we charge is included in the total purchase price we pay for a life insurance policy for purposes of our valuation and expected internal rate of return calculations, but is not netted against the purchase price we pay to a seller of an insurance policy. We generated cash flows of \$153,000 and \$1,462,000 from origination fees during the three and nine months ended September 30, 2014, and \$1,004,000 and \$2,818,000 during the same periods in 2013. Profit from intra-company origination fees for life insurance policies retained by the Company are eliminated from our consolidated statements of operations. As such, the origination fees collected under our life insurance policy financing arrangements are reflected in our consolidated statements of cash flows as cash flows from financing activities as they are received from borrowings used to finance the acquisition of life insurance policies. Our revolving bank line allows DLP II to borrow the funds necessary to pay origination fees to GWG Life. Our borrowing agreements allow us to use net proceeds of the Renewable Secured Debentures for policy acquisition, which includes origination fees. If the policy acquisition is not financed, no fees are included in the consolidated cash flows. See "Cash Flows" below for further information. We determine the purchase price of life insurance policies in accordance with ASC 325-30, Investments in Insurance Contracts, using the fair value method. Under the fair value method, the initial investment is recorded at the transaction price. Because the origination fees are paid from a wholly owned subsidiary to the parent company, these fees are not included in the transaction price as reflected in our consolidated financial statements. For further discussion on our accounting policies for life settlements, please refer to note 1 to our consolidated financial statements.

As of September 30, 2014, we had approximately \$41.1 million in combined available cash and available borrowing base surplus capacity under our revolving credit facility for the purpose of purchasing additional life insurance policies, paying premiums on existing policies, paying portfolio servicing expenses, and paying principal and interest on our outstanding financing obligations.

In September 2012, we concluded a Series A preferred stock offering, receiving an aggregate \$24.6 million in subscriptions for our Series A preferred stock. These subscriptions consisted of \$14.0 million in conversions of outstanding Series I Secured notes and \$10.6 million of new investments. We have used the proceeds from the sale of our Series A preferred stock, together with the origination fees we received to purchase and finance life insurance policies to fund our operational expenditures.

In June 2011, we registered a \$250.0 million debt offering of our Renewable Secured Debentures with the SEC. The registration became effective on January 31, 2012. Through September 30, 2014, the total amount of Renewable Secured Debentures sold, including renewals, is \$225.0 million. As of September 30, 2014, we had approximately \$173.2 million in principal amount of Renewable Secured Debentures outstanding.

On September 24, 2014, GWG consummated an initial public offering of its common stock which resulted in the sale of 800,000 shares of common stock at \$12.50 per share. The sale resulted in net proceeds of approximately \$9.03 million after the deduction of underwriting commissions, discounts and expense reimbursements. The company intends to use the net proceeds from the offering to promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in the secondary market for life insurance policies, purchase additional life insurance policies in the secondary market, pay premiums on the company's life insurance policy assets, fund its portfolio operations, and for working capital purposes.

Additionally, our wholly owned subsidiary GWG Life issued Series I Secured notes beginning in November 2009 on a private placement basis to accredited investors only. As of September 30, 2014, we had approximately \$28.2 million in principal amount of Series I Secured notes outstanding. This offering was closed in November 2011.

The weighted-average interest rate of our outstanding Series I Secured notes as of September 30, 2014 and December 31, 2013 was 8.37% and 8.35%, respectively, and the weighted average maturity at those dates was 1.92 and 2.49 years, respectively. The Series I Secured notes have renewal features. Since we first issued our Series I Secured notes, we have experienced \$131,774,000 in maturities, of which as of September 30, 2014, \$102,260,000 has renewed for an additional term. This has provided us with an aggregate renewal rate of approximately 78% for investments in our subsidiary secured notes. Future contractual maturities of Series I Secured notes payable at September 30, 2014 are:

Years Ending December 31,	
Three months ending December 31, 2014	\$1,925,000
2015	12,729,000
2016	8,217,000
2017	4,427,000
2018	754,000
Thereafter	141,000
	\$28,193,000

The weighted-average interest rate of our outstanding Renewable Secured Debentures as of September 30, 2014 and December 31, 2013 was 7.49% and 7.53%, respectively, and the weighted average maturity at those dates was 3.50 and 3.69 years, respectively. Our Renewable Secured Debentures have renewal features. Since we first issued our Renewable Secured Debentures, we have experienced \$51,493,000 in maturities, of which as of September 30, 2014, \$34,105,000 has renewed for an additional term. This has provided us with an aggregate renewal rate of approximately 66% for investments in our Renewable Secured Debentures. Future contractual maturities of Renewable Secured Debentures at September 30, 2014 are:

Years Ending December 31,	
Three months ending December 31, 2014	\$16,086,000
2015	55,676,000
2016	43,434,000
2017	21,950,000
2018	10,730,000
Thereafter	25,369,000
	\$173,245,000

The Renewable Secured Debentures and Series I Secured notes are secured by all our assets, and are subordinate to our revolving credit facility with Autobahn/DZ Bank. The Renewable Secured Debentures and Series I Secured notes are pari passu with respect to our assets pursuant to an intercreditor agreement (see notes 7 and 8 to our consolidated financial statements).

We maintain a \$100 million revolving credit facility with Autobahn/DZ Bank through GWG Life's wholly owned subsidiary DLP II. As of September 30, 2014 and December 31, 2013 we had \$79.0 million outstanding under the revolving credit facility and maintained an available borrowing base surplus of \$11.6 and \$3.9 million, respectively (see note 6 to our consolidated financial statements).

We expect to meet our ongoing operational capital needs through a combination of policy benefit revenues, origination fees, and proceeds from financing transactions. We expect to meet our policy acquisition, servicing, and financing capital needs principally from the receipt of policy benefit revenues from our portfolio of life insurance policies, net proceeds from our offering of Renewable Secured Debentures, and from our revolving credit facility. Because we only receive origination fees when we purchase a policy, our receipt of those fees is contingent upon our consummation of policy purchases, which is, in turn, contingent upon our receipt of external funding. Despite recent adverse capital market conditions, including a prolonged credit crisis, we have demonstrated continued access to credit and financing markets. Furthermore, we expect to begin receiving insurance benefit payments on our portfolio of life insurance policies as the average age of the insureds increase and mortality events occur over time which we expect to begin more significantly in 2015 and steadily increasing until 2018. As a result of the foregoing, we estimate that our liquidity and capital resources are sufficient for our current and projected financial needs. Nevertheless, if we are unable to continue our offering of Renewable Secured Debentures for any reason (or if we become unsuccessful in selling debentures), and we are unable to obtain capital from other sources, we expect that our business would be materially and adversely affected. In addition, our business would be materially and adversely affected if we did not receive the policy benefits we forecast and if holders of our Renewable Secured Debentures or Series I Secured notes failed to renew with the frequency we have historically experienced. In such a case, we could be forced to sell our investments in life insurance policies to service or satisfy our debt-related obligations and continue to pay policy premiums.

Capital expenditures have historically not been material and we do not anticipate making material capital expenditures in 2014 or beyond.

Debt Financings Summary

We had the following outstanding debt balances as of September 30, 2014:

Issuer/Borrower	Principal Amount Outstanding	Weighted Average Interest Rate	đ
GWG Holdings, Inc Renewable Secured Debentures	\$173,245,000	7.49	%
GWG Life Settlements, LLC -Series I Secured notes	28,193,000	8.37	%
GWG DLP Funding II, LLC - Revolving credit facility	79,000,000	6.22	%
Total	\$280,438,000	7.22	%

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

Our total credit facility and other indebtedness balance as of September 30, 2014 and December 31, 2013 was \$280,438,000 and \$243,635,000, respectively. At September 30, 2014, the total outstanding face amount under our Series I Secured notes outstanding was \$28,193,000, less unamortized selling costs of \$491,000, resulting in a carrying amount of \$27,702,000. At December 31, 2013, the total outstanding face amount under our Series I Secured notes outstanding was \$29,744,000, less unamortized selling costs of \$469,000, resulting in a carrying amount of \$29,275,000. At September 30, 2014, the total outstanding face amount of Renewable Secured Debentures was \$173,245,000 plus \$1,679,000 of subscriptions in process, less unamortized selling costs of \$5,737,000, resulting in a carrying amount of \$169,187,000. At December 31, 2013, the total outstanding face amount of Renewable Secured Debentures outstanding was \$134,891,000 plus \$1,902,000 of subscriptions in process, less unamortized selling costs of \$5,147,000, resulting in a carrying amount of \$131,646,000. At September 30, 2014, the fair value of our investments in life insurance policies of \$276,382,000 plus our cash balance of \$29,512,000 and our restricted cash balance of \$2,145,000, totaled \$308,039,000, representing an excess of portfolio assets over secured indebtedness of \$27,601,000. At December 31, 2013, the fair value of our investments in life insurance policies of \$234,673,000 plus our cash balance of \$33,450,000 and our restricted cash balance of \$5,833,000, totaled \$273,956,000, representing an excess of portfolio assets over secured indebtedness of \$30,321,000. The Renewable Secured Debentures and Series I Secured notes are secured by all our assets and are subordinate to our revolving credit facility with Autobahn/DZ Bank. The Renewable Secured Debentures and Series I Secured notes are pari passu with respect to shared collateral pursuant to an intercreditor agreement.

The following forward-looking table seeks to illustrate the impact of the sale of our portfolio of life insurance assets at various discount rates in order to satisfy our debt obligations as of September 30, 2014. In all cases, the sale of the life insurance assets owned by DLP II will be used first to satisfy all amounts owing under the revolving credit facility with Autobahn/ DZ Bank. The net sale proceeds remaining after satisfying all obligations under the revolving credit facility would be applied to Renewable Secured Debentures and Series I Secured notes on a pari passu basis.

Portfolio Discount Rate	10%	11%	12%	13%	14%
Value of portfolio	\$298,167,000	\$283,889,000	\$270,713,000	\$258,529,000	\$247,240,000
Cash and cash equivalents	31,657,000	31,657,000	31,657,000	31,657,000	31,657,000
Total assets	329,824,000	315,546,000	302,370,000	290,186,000	278,897,000
Revolving credit facility Autobahn/DZ Bank	79,000,000	79,000,000	79,000,000	79,000,000	79,000,000
Net after revolving credit facility	250,824,000	236,546,000	223,370,000	211,186,000	199,897,000
Series I Secured notes and Renewable Secured Debentures	201,438,000	201,438,000	201,438,000	201,438,000	201,438,000
Net after Series I Secured notes and Renewable Secured Debentures	\$49,386,000	\$35,108,000	\$21,932,000	\$9,748,000	\$(1,541,000)
Impairment to Series I Secured notes and Renewable Secured Debentures	No impairment	No impairment	No impairment	No impairment	Impairment

The table illustrates that our ability to fully satisfy amounts owing under the Renewable Secured Debentures and Series I Secured notes would likely be impaired upon the sale of all our life insurance assets at a price equivalent to a discount rate of approximately 13.86% or higher. The discount rates used to calculate the fair value of our portfolio for mark-to-market accounting were 11.56% and 11.69% as of September 30, 2014 and December 31, 2013, respectively. The table does not include any allowance for transactional fees and expenses associated with a portfolio sale (which expenses and fees could be substantial), and is provided to demonstrate how various discount rates used to value our portfolio could affect our ability to satisfy amounts owing under our debt obligations, in light of our senior secured lender's right to priority payments. You should read the above table in conjunction with the information contained in other sections of this report, including our discussion of discount rates included under the "—Critical Accounting Policies – Valuation of Insurance Policies" caption above. This discussion and analysis is based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. The forward-looking presentation above is subject to numerous risks and uncertainties. Our actual results could differ materially from those suggested or implied by the above table. Please see the caption "Risk Relating to Forward-Looking Statements" above.

On May 29, 2014, GWG Holdings, together with GWG Life and DLPII, entered into an Amendment No. 1 to Amended and Restated Credit and Security Agreement with Autobahn and DZ Bank (as committed lender and Agent). The amendment was entered into for the purpose of extending the maturity date for borrowings under the agreement to December 31, 2016.

On July 3, 2014, we filed a registration statement on Form S-1 (File No. 333-197227), as subsequently amended, for the public offer and sale of up to an aggregate of \$1,000,000,000 of secured debt named "L Bonds." The L Bonds have terms substantially identical to the Renewable Secured Debentures, and are to be issued under the same indenture, as amended and contemplated to be amended. Upon effectiveness of the L Bond offering, a pending amendment to the

indenture will rename our outstanding "Renewable Secured Debentures" as "L Bonds."

Cash Flows

The payment of premiums and servicing costs to maintain life insurance policies represents our most significant requirement for cash disbursement. When a policy is purchased, we are able to calculate the minimum premium payments required to maintain the policy in-force. Over time as the insured ages, premium payments will increase; however, the probability of actually needing to pay the premiums decreases since mortality becomes more likely. These scheduled premiums and associated probabilities are factored into our expected internal rate of return and cash-flow modeling described herein. Beyond premiums, we incur policy servicing costs, including annual trustee and tracking costs, and debt servicing costs, including principal and interest payments. Until we receive a stable amount of proceeds from the policy benefits, we intend to pay these costs from our credit facility, when permitted, and through the issuance of debt securities, including Renewable Secured Debentures.

For the quarter end dates set forth below, the following table illustrates the total amount of face value of policy benefits owned, and the trailing 12 months of life insurance policy benefits collected and premiums paid on our portfolio. The trailing 12-month benefits/premium coverage ratio indicates the ratio of policy benefits received to premiums paid over the trailing 12-month period from our portfolio of life insurance policies.

				12-Month	1
	Portfolio	12-Month	12-Month	Trailing	
	Face	Trailing	Trailing	Benefits/	
	Amount	Benefits	Premiums	Premium	
	Amount	Collected	Paid	Coverage	
Quarter End Date				Ratio	
March 31, 2012	\$482,455,000	\$4,203,000	\$14,977,000	28.06	%
June 30, 2012	489,255,000	8,703,000	15,412,000	56.47	%
September 30, 2012	515,661,000	7,833,000	15,837,000	49.46	%
December 31, 2012	572,245,000	7,350,000	16,597,000	44.28	%
March 31, 2013	639,755,000	11,350,000	18,044,000	62.90	%
June 30, 2013	650,655,000	13,450,000	19,182,000	70.11	%
September 30, 2013	705,069,000	18,450,000	20,279,000	90.98	%
December 31, 2013	740,648,000	16,600,000	21,733,000	76.38	%
March 31, 2014	771,940,000	12,600,000	21,930,000	57.46	%
June 30, 2014	784,652,000	6,300,000	22,598,000	27.88	%
September 30, 2014	787,964,000	4,300,000	23,121,000	18.60	%

We believe that the portfolio cash flow results set forth above represent our general investment thesis: that the life insurance policy benefits we receive will continue to increase over time in relation to the premiums we are required to pay on the remaining polices in the portfolio. Nevertheless, we expect that our portfolio cash flow results will remain inconsistent until such time we achieve our goal of acquiring a larger, more diversified portfolio of life insurance policies in order to obtain more normalized actuarial results. For example, we had expected to receive a greater amount of insurance benefits for the periods ended December 31, 2013 and September 30, 2014 than we actually experienced. As our receipt of life insurance policy benefits increase, we expect to begin servicing and paying down our outstanding indebtedness, or alternatively purchasing additional life insurance policies, from these cash flows. As indicated above under "Liquidity and Capital Resources," we presently expect that by 2015, the cash inflows from the receipt of policy benefits will exceed the premium obligations on the remaining life insurance policies held within the portfolio as of December 31, 2013.

The amount of payments for anticipated premiums and servicing costs that we will be required to make over the next five years to maintain our current portfolio, assuming no mortalities, is set forth in the table below.

	Premiums
Year	and
	Servicing
Three months ending December 31, 2014	\$6,711,000
2015	27,075,000
2016	29,701,000
2017	33,176,000
2018	36,100,000

Total

Edgar Filing: GWG Holdings, Inc. - Form 10-Q

\$132,763,000

The life insurance policies owned by DLP II are subject to a collateral arrangement with the agent to our revolving credit lender, as described in note 6 to the consolidated financial statements. Under this arrangement, collection and escrow accounts are used to fund purchases and premiums of the insurance policies and to pay interest and other charges under our revolving credit facility. The lender and its agent must authorize all disbursements from these accounts, including any distributions to GWG Life or GWG Holdings. Distributions are limited to an amount that would result in the borrowers (DLP II, GWG Life, and GWG Holdings) realizing an annualized rate of return on the equity funded amount for such assets of not more than 18%, as determined by the agent. After such amount is reached, the credit agreement requires that excess funds be used to fund repayments or a reserve account in a certain amount before any additional distributions may be made. In the future, these arrangements may restrict the cash flows available for payment of principal and interest on our debt obligations.

Inflation

Changes in inflation do not necessarily correlate with changes in interest rates. We presently do not foresee any material impact of inflation on our results of operations in the periods presented in our consolidated financial statements.

Off-Balance Sheet Arrangements

Operating Lease - We entered into an office lease with U.S. Bank National Association as the landlord. The lease was effective April 22, 2012 with a term through August 31, 2015. The lease is for 11,695 square feet of office space located at 220 South Sixth Street, Minneapolis, Minnesota. We are obligated to pay base rent plus common area maintenance and a share of the building operating costs. Minimum lease payments under the lease are as follows:

Three months ending December 31, 2014	\$26,000
2015	70,000
Total	\$96,000

Credit Risk

We review the credit risk associated with our portfolio of life insurance policies when estimating its fair value. In evaluating the policies' credit risk we consider insurance company solvency, credit risk indicators, economic conditions, ongoing credit evaluations, and company positions. We attempt to manage our credit risk related to life insurance policies typically by purchasing policies issued only from companies with an investment grade credit rating by either Standard & Poor's, Moody's, or A.M. Best Company. As of September 30, 2014, 99.08% of our life insurance policies, by face value benefits, were issued by companies that maintained an investment grade rating (BBB or better) by Standard & Poor's.

Interest Rate Risk

Our credit facility is floating-rate financing. In addition, our ability to offer interest rates that attract capital (including in the offer and sale of Renewable Secured Debentures) is generally impacted by prevailing interest rates. Furthermore, while our other indebtedness provides us with fixed-rate financing, our debt coverage ratio is calculated in relation to our total cost of financing. Therefore, fluctuations in interest rates impact our business by increasing our borrowing costs, and reducing availability under our debt financing arrangements. Furthermore, we calculate our portfolio earnings based upon the spread generated between the return on our life insurance portfolio and the cost of our financing. As a result, increases in interest rates will reduce the earnings we expect to achieve from our investments in life insurance policies.

Non-GAAP Financial Measures

We use non-GAAP financial measures when evaluating our financial results, for planning and forecasting purposes, and for maintaining compliance with covenants contained in our borrowing agreements. Non-GAAP financial measures disclosed by management are provided as additional information to investors in order to provide them with an alternative method for assessing our financial condition and operating results. These non-GAAP financial measures are not in accordance with GAAP and may be different from non-GAAP measures used by other companies, including other companies within our industry. This presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for comparable amounts prepared in accordance with GAAP. See the notes to our consolidated financial statements and our audited financial statements contained herein.

We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, *Investments in Life Insurance Contracts*. Accordingly, we value our investments in life insurance policies at the conclusion of each reporting period in accordance with GAAP fair value accounting principles. In addition to GAAP, we are required to report non-GAAP financial measures to Autobahn/DZ Bank under certain financial covenants made to that lender under our revolving credit facility. As indicated above, we also use non-GAAP financial reporting to manage and evaluate the financial performance of our business.

GAAP-based fair value requires us to mark-to-market our investments in life insurance policies, which by its nature, is based upon Level 3 measurements that are unobservable. As a result, this accounting treatment imports financial market volatility and subjective inputs into our financial reporting. We believe this type of accounting reporting is at odds with one of the key attractions for purchasing and owning a portfolio life insurance policies: the non-correlated nature of the returns to be derived from such policies. Therefore, in contrast to a GAAP-based fair valuation, we seek to measure the accrual of the actuarial gain occurring within the portfolio of life insurance policies at their expected internal rate of return based on statistical mortality probabilities for the insureds (using primarily the insured's age, sex and smoking status). The expected internal rate of return tracks actuarial gain occurring within the policies according to a mortality table as the insureds' age increases. By comparing the actuarial gain accruing within our portfolio of life insurance policies against our costs during the same period, we can estimate, manage and evaluate the overall financial profitability of our business without regard to mark-to-market volatility. We use this information to balance our life insurance policy purchasing and manage our capital structure, including the issuance of debt and utilization of our other sources of capital, and to monitor our compliance with borrowing covenants. We believe that these non-GAAP financial measures provide information that is useful for investors to understand period-over-period operating results separate and apart from fair value items that may, or could, have a disproportionately positive or negative impact on results in any particular period.

Our credit facility requires us to maintain a "positive net income" and "tangible net worth" each of which are calculated on an adjusted non-GAAP basis on the method described above, without regard to GAAP-based fair value measures. In addition, our revolving credit facility requires us to maintain an "excess spread," which is the difference between (i) the weighted average of our expected internal rate of return of our portfolio of life insurance policies and (ii) the weighted average of our credit facility's interest rate. These calculations are made using non-GAAP measures in the method described below, without regard to GAAP-based fair value measures.

In addition, our Renewable Secured Debentures and Series I Secured notes require us to maintain a "debt coverage ratio" designed to ensure that the expected cash flows from our portfolio of life insurance policies is able to adequately service our total outstanding indebtedness. In addition, our Renewable Secured Debentures requires us to maintain a "subordination ratio" which limits the total amount of indebtedness that can be issued senior in rank to the Renewable Secured Debentures and Series I Secured notes. These ratios are calculated using non-GAAP measures in the method described below, without regard to GAAP-based fair value measures.

Adjusted Non-GAAP Net Income. Our credit facility requires us to maintain a positive net income calculated on an adjusted non-GAAP basis. We calculate the adjusted net income by recognizing the actuarial gain accruing within our life insurance policies at the expected internal rate of return of the policies we own without regard to fair value. We net this actuarial gain against our costs during the same period to calculate our net income on a non-GAAP basis.

	Three Months	Ended	Nine Months E	Ended
	September 30	,	September 30,	
	2014	2013	2014	2013
GAAP net income (loss)	\$(3,400,000)	\$(1,629,000)	\$(7,888,000)	\$195,000
Unrealized fair value gain (1)	(8,762,000)	(6,960,000)	(30,973,000)	(25,904,000)
Adjusted cost basis increase (2)	10,982,000	9,360,000	33,156,000	28,256,000
Accrual of unrealized actuarial gain (3)	8,082,000	5,208,000	23,209,000	15,406,000
Total adjusted non-GAAP income (4)	\$6,902,000	\$5,979,000	\$17,504,000	\$17,953,000

(1)Reversal of unrealized fair value gain of life insurance policies for current period.

(2) Adjusted cost basis is increased to include those acquisition and servicing expenses which are not capitalized by GAAP.

(3) Accrual of actuarial gain at expected internal rate of return based on investment cost basis for the period.

We must maintain an annual positive consolidated net income, calculated on a non-GAAP basis, to maintain (4)

compliance with our revolving credit facility with DZ Bank/Autobahn.

Adjusted Non-GAAP Tangible Net Worth. Our revolving credit facility requires us to maintain a tangible net worth in excess of \$15 million calculated on an adjusted non-GAAP basis. We calculate the adjusted tangible net worth by recognizing the actuarial gain accruing within our life insurance policies at the expected internal rate of return of the policies we own without regard to fair value. We net this actuarial gain against our costs during the same period to calculate our tangible net worth on a non-GAAP basis.

	As of	As of
	September 30,	December 31,
	2014	2013
GAAP net worth (1)	\$20,221,000	\$19,231,000
Less intangible assets (2)	(8,237,000)	(6,068,000)
GAAP tangible net worth	11,984,000	13,163,000
Unrealized fair value gain (3)	(145,717,000)	(114,744,000)
Adjusted cost basis increase (4)	139,094,000	106,201,000
Accrual of unrealized actuarial gain (5)	72,875,000	49,666,000
Total adjusted non-GAAP tangible net worth (6)	\$78,236,000	\$54,286,000

(1) Includes termination of redeemable member's interest prior to corporate conversion and preferred stock classified as temporary equity.

(2) Unamortized portion of deferred financing costs and pre-paid insurance.

(3) Reversal of cumulative unrealized fair value gain or loss of life insurance policies.

(4) Adjusted cost basis is increased by acquisition and servicing expenses which are not capitalized under GAAP.

(5) Accrual of cumulative actuarial gain at expected internal rate of return based on investment cost basis.

(6) We must maintain a total adjusted non-GAAP tangible net worth of \$15 million to maintain compliance with our revolving credit facility with DZ Bank/Autobahn.

Excess Spread. Our revolving credit facility requires us to maintain a 2.00% "excess spread" between our weighted-average expected internal rate of return of our portfolio of life insurance policies and the credit facility's interest rate. A presentation of our excess spread and our total excess spread is set forth below. Management uses the "total excess spread" to gauge expected profitability of our investments, and uses the "excess spread" to monitor compliance with our borrowing.

	As of		As of	
	March 31	,	December	31,
	2014		2013	
Weighted-average expected IRR (1)	11.88	%	12.21	%
Weighted-average revolving credit facility interest rate (2)	6.22	%	6.19	%
Excess spread (3)	5.66	%	6.02	%
Total weighted-average interest rate on indebtedness for borrowed money (4)	7.22	%	7.20	%
Total excess spread	4.66	%	5.01	%

This represents the weighted-average expected internal rate of return of the life insurance policies as of the measurement date based upon our investment cost basis of the insurance policies and the expected cash flows from the life insurance portfolio. Our investment cost basis is calculated as our cash investment in the life insurance policies, without regard to GAAP-based fair value measurements, and is set forth below:

	As of	As of
Investment Cost Basis	September 30,	December 31,
	2014	2013
GAAP fair value	\$276,382,000	\$234,673,000
Unrealized fair value gain (A)	(145,717,000)	(114,744,000)
Adjusted cost basis increase (B)	139,094,000	106,201,000
Investment cost basis (C)	\$269,759,000	\$226,130,000

(A) This represents the reversal of cumulative unrealized GAAP fair value gain of life insurance policies.

(B) $\stackrel{Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP.$

This is the full cash investment cost basis in life insurance policies from which our expected internal rate of return $(C)^{is}$ calculated.

(2) This is the weighted-average revolving credit relating to our revolving credit facility interest rate as of the measurement date.

(3) We must maintain an excess spread of 2.00% relating to our revolving credit facility to maintain compliance under such facility.

(4) Represents the weighted-average interest rate paid on all outstanding indebtedness as of the measurement date, determined as follows:

	As of	As of
	September 30,	December 31,
Outstanding Indebtedness	2014	2013
Revolving credit facility	\$79,000,000	\$79,000,000
Series I Secured notes	28,193,000	29,744,000
Renewable Secured Debentures	173,245,000	134,891,000
Total	\$280,438,000	\$243,635,000

Interest Rates on Indebtedness		
Revolving credit facility	6.22%	6.19%
Series I Secured notes	8.37%	8.35%
Renewable Secured Debentures	7.49%	7.53%
Weighted-average interest rates on indebtedness	7.22%	7.20%

Debt Coverage Ratio and Subordination Ratio. Our Renewable Secured Debentures and Series I Secured notes require us to maintain a "debt coverage ratio" of less than 90%. The "debt coverage ratio" is calculated by dividing the sum of our total indebtedness by the sum of our cash and cash equivalents and the net present value of the life insurance portfolio. The "subordination ratio" for our Renewable Secured Debentures is calculated by dividing the total indebtedness that is senior to Renewable Secured Debentures and Series I Secured notes by the sum of the company's cash and cash equivalents and the net present value of the life insurance portfolio. The "subordination ratio" must be less than 50%. For purposes of both ratio calculations, the net present value of the life insurance portfolio is calculated using a discount rate equal to the weighted average interest rate of all indebtedness.

	As of	As of
	September 30,	December 31,
	2014	2013
Life insurance portfolio policy benefits	\$787,964,000	\$740,648,000
Discount rate of future cash flows	7.22	% 7.20 %
Net present value of Life insurance portfolio policy benefits	\$344,774,000	\$302,761,000
Cash and cash equivalents	31,657,000	39,283,000
Total Coverage	376,431,000	342,044,000
Revolving credit facility	79,000,000	79,000,000
Series I Secured notes	28,193,000	29,744,000
Renewable Secured Debentures	173,245,000	134,891,000
Total Indebtedness	\$280,438,000	\$243,635,000
Debt Coverage Ratio	74.50	% 71.23 %
Subordination Ratio	20.99	% 23.10 %

As of September 30, 2014, we were in compliance with both the debt coverage ratio and the subordination ratio as required under our related financing agreements for Renewable Secured Debentures and Series I Secured notes.

Our Portfolio

Our portfolio of life insurance policies, owned by our subsidiaries as of September 30, 2014, is summarized below:

Life Insurance Portfolio Summary

Total portfolio face value of policy benefits Average face value per policy	\$787,964,000 \$2,727,000)
Average face value per insured life	\$2,996,000	
Average age of insured (yrs.) *	82.6	
Average life expectancy estimate (yrs.) *	6.69	
Total number of policies	289	
Number of unique lives	263	
Demographics	68% Males; 32% Females	
Number of smokers	3	
Largest policy as % of total portfolio	1.27	%
Average policy as % of total portfolio	0.35	%
Average Annual Premium as % of face value	3.31	%

* Averages presented in the table are weighted averages.

Our portfolio of life insurance policies, owned by our subsidiaries as of September 30, 2014, organized by the insured's current age and the associated policy benefits, is summarized below:

Distribution of Policy Benefits by Current Age of Insured

Min Age	Max Age	Policy Benefits	Weighted Average Life Expectancy (yrs.)	Distributio	n
65	69	\$9,157,000	7.66	1.16	%
70	74	47,767,000	8.72	6.06	%
75	79	172,048,000	8.38	21.83	%
80	84	289,260,000	7.20	36.71	%
85	89	237,464,000	4.82	30.14	%
90	95	32,268,000	3.59	4.10	%
Total		\$787,964,000	6.69	100.00	%

Our portfolio of life insurance policies, owned by our subsidiaries as of September 30, 2014, organized by the insured's current age and number of policies owned, is summarized below:

Distribution of Policies by Current Age of Insured

Min Age	Max Age	Policies	Weighted Average Life Expectancy (yrs.)	Distributio	n
65	69	8	7.66	2.77	%
70	74	20	8.72	6.92	%
75	79	57	8.38	19.72	%
80	84	99	7.20	34.26	%
85	89	90	4.82	31.14	%
90	95	15	3.59	5.19	%
Total		289	6.69	100.00	%

Our portfolio of life insurance policies, owned by our subsidiaries as of September 30, 2014, organized by the insured's estimated life expectancy estimates and associated policy benefits, is summarized below:

Distribution of Policy Benefits by Current Life Expectancies of Insured

Min LE (Months)	Max LE (Months)	Policy Benefits	Distribution	
144	167	\$9,000,000	1.14	%
120	143	69,656,000		70 76
	145	175,024,000		70 %
96 72				
72	95	203,081,000		% ~
48	71	209,573,000		%
16	47	121,630,000		%
Total		\$787,964,000	100.00	%

We track concentrations of pre-existing medical conditions among insured individuals within our portfolio based on information contained in life expectancy reports. We track these medical conditions with ten primary disease categories: (1) cardiovascular, (2) cerebrovascular, (3) dementia, (4) cancer, (5) diabetes, (6) respiratory disease, (7) neurological disorders, (8) other, no disease, or multiple. Our primary disease categories are summary generalizations based on the ICD-9 codes we track on each insured individuals within our portfolio. ICD-9 codes, published by the World Health Organization, are used worldwide for medical diagnoses and treatment systems, as well as morbidity and mortality statistics. Currently, cardiovascular is the only primary disease category within our portfolio that represents a concentration over 10%.

Our portfolio of life insurance policies, owned by our subsidiaries as of September 30, 2014, organized by the primary disease categories of the insured and associated policy benefits, is summarized below:

Distribution of Policy Benefits by Primary Disease Category

Primary Disease Category	Policy Benefits	Distributio	n
Cancer	\$57,450,000	7.29	%
Cardiovascular	141,874,000	18.00	%
Cerebrovascular	21,960,000	2.79	%
Dementia	62,699,000	7.96	%
Diabetes	63,617,000	8.07	%
Multiple	202,109,000	25.65	%
Neurological Disorders	16,104,000	2.04	%
No Disease	94,468,000	11.99	%
Other	86,483,000	10.98	%
Respiratory Diseases	41,200,000	5.23	%
Total Policy Benefits	\$787,964,000	100.00	%

The primary disease category represents a general category of impairment. Within the primary disease category, there are a multitude of sub-categorizations defined more specifically by ICD-9 codes. For example, a primary disease category of cardiovascular includes subcategorizations such as atrial fibrillation, heart valve replacement, coronary atherosclerosis, etc. In addition, individuals may have more than one ICD-9 code describing multiple medical conditions within one or more primary disease categories. Where an individual's ICD-9 codes indicate medical conditions in more than one primary disease categories, we categorize the individual as having multiple primary disease categories. We expect to continue to develop and refine our identification and tracking on the insured individuals medical conditions as we manage our portfolio of life insurance policies.

Portfolio Credit Risk Management

The life insurance policies that we acquire represent obligations of third-party life insurance companies to pay the benefits under the relevant policy. Because we finance life insurance policies, we rely on the payments from the face value of policy benefits from life insurance companies for revenue collections. We rely on the face value of the life insurance policy benefit at maturity as the exclusive form of payment.

The possible insolvency or loss by a life insurance company is a significant risk to our business. To manage this risk, we seek to purchase policies that are issued by insurance companies with investment-grade ratings from either A.M. Best, Moody's or Standard & Poor's. To further mitigate risk, we seek to limit the face value of policy benefits issued by any one life insurance company within the total portfolio to 20%. State guaranty funds generally guaranty policy benefits up to \$200,000. In addition, to assure diversity and stability in our portfolio, we regularly review the various metrics of our portfolio relating to credit risk. We track industry rating agency reports and industry journals and articles in order to gain insight into possible financial problems of life insurance companies. Recently, some of the

credit ratings on insurance companies were downgraded and we will no longer consider purchasing policies issued by these insurance companies. Finally, we will only purchase those life insurance policies that meet the underwriting standards established in the indenture governing our Renewable Secured Debentures.

As of September 30, 2014, 99.87% of insurance companies in our portfolio hold an investment-grade rating by Standard & Poor's (BBB- or better), and the face value of policy benefits issued by one life insurance company within the portfolio was 15.66%. Of the 44 insurance companies that insure the policies we own, ten companies insure approximately 72.80% of total face value of insurance benefits and the remaining 34 insurance companies insure the remaining approximately 27.20% of total face value of insurance benefits. The concentration risk of our ten largest insurance company holdings as of September 30, 2014 is set forth in the table below.

Rank	Policy Benefits	Percentage of Policy Benefit Amt.	•	Insurance Company	Ins. Co. S&P Rating
1	\$123,380,000	15.66	%	AXA Equitable Life Insurance Company	A+
2	\$89,470,000	10.35	%	John Hancock Life Insurance Company (U.S.A)	AA-
3	\$73,920,000	9.38	%	Transamerica Life Insurance Company	AA-
4	\$58,769,000	7.46	%	Jefferson-Pilot Life Insurance Company	AA-
5	\$56,215,000	7.13	%	ING Life Insurance and Annuity Company	A-
6	\$43,550,000	5.53	%	American General Life Insurance Company	A+
7	\$42,735,000	5.42	%	Massachusetts Mutual Life Insurance Company	AA+
8	\$30,500,000	3.87	%	Pacific Life Insurance Company	A+
9	\$28,450,000	3.61	%	West Coast Life Insurance Company	AA-
10	\$26,661,000	3.38	%	Metropolitan Life Insurance Company	AA-

Life Insurance Portfolio Detail

(as of September 30, 2014)

Face	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
Amount 1 \$1,100,000	м	94	31.7	ING Life Insurance and Annuity Company	A-
2 \$4,000,000		94 93	37.5	MetLife Investors USA Insurance Company	A- AA-
3 \$1,770,726		93	35.7	Aviva Life Insurance Company	A-
4 \$3,200,000		93	61.0	West Coast Life Insurance Company	A- AA-
5 \$1,000,000		92	41.9	Transamerica Life Insurance Company	AA-
	F	92	27.5	Lincoln Benefit Life Company	BBB+
7 \$2,500,000		91	25.4	Columbus Life Insurance Company	AA
8 \$500,000	M	91	20.6	John Hancock Life Insurance Company (U.S.A)	AA-
9 \$2,000,000		91	19.3	Pruco Life Insurance Company (0.5.77)	AA-
10\$250,000	M	91	24.9	Transamerica Life Insurance Company	AA-
11\$1,682,773		90	56.9	Hartford Life and Annuity Insurance Company	BBB+
12\$3,000,000		90	53.4	West Coast Life Insurance Company	AA-
13\$5,000,000		90	58.7	American General Life Insurance Company	A+
14\$5,000,000		90	38.5	John Hancock Life Insurance Company (U.S.A)	AA-
15\$1,000,000		90	35.7	Protective Life Insurance Company (0.5.77)	AA-
16\$5,000,000		89	37.9	John Hancock Life Insurance Company (U.S.A)	AA-
17\$3,500,000		89	62.7	John Hancock Life Insurance Company (U.S.A)	AA-
18\$3,100,000		89	39.6	Lincoln Benefit Life Company (0.5.14)	BBB+
19\$1,500,000		89	72.9	Jefferson-Pilot Life Insurance Company	AA-
20\$1,000,000		89	31.9	State Farm Life Insurance Company	AA-
21\$3,000,000		89	39.2	Jefferson-Pilot Life Insurance Company	AA-
22\$5,000,000		89	46.1	ING Life Insurance and Annuity Company	A-
23\$5,000,000		89	23.4	Lincoln National Life Insurance Company	AA-
24\$1,000,000		89	13.1	ING Life Insurance and Annuity Company	A-
25\$1,203,520		89	49.9	Columbus Life Insurance Company	AA
26\$1,350,000		89	41.6	Jefferson-Pilot Life Insurance Company	AA-
27\$600,000	F	89	26.9	Columbus Life Insurance Company	AA
28\$5,000,000		88	54.6	Massachusetts Mutual Life Insurance Company	AA+
29\$2,500,000		88	54.3	American General Life Insurance Company	A+
30\$2,500,000		88	45.7	Pacific Life Insurance Company	A+
31\$1,000,000		88	56.9	United of Omaha Life Insurance Company	A+
32\$1,000,000		88	72.4	Transamerica Life Insurance Company	AA-
33\$250,000	F	88	72.4	Transamerica Life Insurance Company	AA-
34\$1,750,000		88	27.4	Transamerica Life Insurance Company	AA-
35\$2,500,000		88	13.1	AXA Equitable Life Insurance Company	A+
36\$2,500,000		88	13.1	AXA Equitable Life Insurance Company	A+
37\$8,985,000		88	37.6	Massachusetts Mutual Life Insurance Company	AA+
38\$715,000	F	88	66.7	Jefferson-Pilot Life Insurance Company	AA-
39\$2,225,000		88	91.3	Transamerica Life Insurance Company	AA-
40\$2,000,000		88	34.8	American General Life Insurance Company	A+

41\$3,500,000	F	88	47.2	Lincoln National Life Insurance Company	AA-
42\$500,000	F	87	75.0	Sun Life Assurance Company of Canada (U.S.)	AA-
43\$250,000	Μ	87	79.0	Metropolitan Life Insurance Company	AA-
44\$4,000,000	F	87	79.0	Transamerica Life Insurance Company	AA-
45\$5,000,000	Μ	87	59.7	AXA Equitable Life Insurance Company	A+
46\$1,500,000	Μ	87	47.5	John Hancock Life Insurance Company (U.S.A)	AA-

	Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
47	\$1,500,000	Μ	87	47.5	John Hancock Life Insurance Company (U.S.A)	AA-
48	\$1,050,000	Μ	87	49.9	John Hancock Life Insurance Company (U.S.A)	AA-
49	\$5,000,000	F	87	37.9	Penn Mutual Life Insurance Company	A+
50	\$1,000,000	Μ	87	61.5	AXA Equitable Life Insurance Company	A+
51	\$500,000	Μ	87	68.1	Lincoln National Life Insurance Company	AA-
52	\$4,785,380	F	87	49.2	John Hancock Life Insurance Company (U.S.A)	AA-
53	\$1,803,455	F	87	55.5	Metropolitan Life Insurance Company	AA-
54	\$1,529,270	F	87	55.5	Metropolitan Life Insurance Company	AA-
55	\$800,000	Μ	87	77.0	Lincoln National Life Insurance Company	AA-
56	\$5,000,000	Μ	87	58.4	John Hancock Life Insurance Company (U.S.A)	AA-
57	\$3,000,000	F	87	88.7	Massachusetts Mutual Life Insurance Company	AA+
58	\$200,000	Μ	87	54.9	Lincoln Benefit Life Company	BBB+
59	\$4,445,467	Μ	87	65.2	Penn Mutual Life Insurance Company	A+
60	\$1,500,000	Μ	87	52.3	Union Central Life Insurance Company	A+
61	\$7,500,000	Μ	87	57.1	Jefferson-Pilot Life Insurance Company	AA-
62	\$3,600,000	F	87	64.4	AXA Equitable Life Insurance Company	A+
63	\$3,000,000	Μ	87	50.4	Jefferson-Pilot Life Insurance Company	AA-
64	\$2,000,000	Μ	87	45.6	John Hancock Life Insurance Company (U.S.A)	AA-
65	\$3,000,000	Μ	87	39.3	American General Life Insurance Company	A+
66	\$1,000,000	Μ	86	67.7	John Hancock Life Insurance Company (U.S.A)	AA-
67	\$2,000,000	Μ	86	67.7	John Hancock Life Insurance Company (U.S.A)	AA-
68	\$5,000,000	Μ	86	55.6	Jefferson-Pilot Life Insurance Company	AA-
69	\$5,000,000	F	86	40.8	Transamerica Life Insurance Company	AA-
70	\$3,000,000	Μ	86	58.8	Transamerica Life Insurance Company	AA-
71	\$1,200,000	Μ	86	67.0	Transamerica Life Insurance Company	AA-
72	\$6,000,000	F	86	63.0	Sun Life Assurance Company of Canada (U.S.)	AA-
73	\$3,000,000	Μ	86	90.5	AXA Equitable Life Insurance Company	A+
74	\$5,570,000	F	86	53.8	ING Life Insurance and Annuity Company	A-
75	\$5,570,000	F	86	53.8	ING Life Insurance and Annuity Company	A-
76	\$1,000,000	F	86	42.0	New York Life Insurance Company	AA+
77	\$10,000,000	F	86	79.1	West Coast Life Insurance Company	AA-
78	\$2,500,000	Μ	86	54.4	Transamerica Life Insurance Company	AA-
79	\$1,000,000	F	86	57.6	West Coast Life Insurance Company	AA-
80	\$2,000,000	F	86	57.6	West Coast Life Insurance Company	AA-
81	\$500,000	F	86	62.1	Beneficial Life Insurance Company	N/A
82	\$800,000	Μ	86	61.9	National Western Life Insurance Company	А
83	\$5,000,000	Μ	86	88.1	Lincoln National Life Insurance Company	AA-
84	\$1,000,000	F	86	33.7	John Hancock Life Insurance Company (U.S.A)	AA-
85	\$4,513,823	F	86	29.3	Aviva Life Insurance Company	A-
86	\$2,000,000	Μ	86	105.6	ING Life Insurance and Annuity Company	A-
87	\$2,000,000	Μ	86	105.6	ING Life Insurance and Annuity Company	A-
88	\$2,000,000	М	86	105.6	ING Life Insurance and Annuity Company	A-
89	\$2,000,000	F	86	82.2	U.S. Financial Life Insurance Company	A+
90	\$1,365,000	F	85	92.1	Transamerica Life Insurance Company	AA-
91	\$1,000,000	F	85	91.6	ING Life Insurance and Annuity Company	A-
92	\$1,000,000	М	85	46.2	Massachusetts Mutual Life Insurance Company	AA+

93 \$2,000,000	Μ	85	91.8	Transamerica Life Insurance Company	AA-
94 \$8,500,000	Μ	85	88.1	Massachusetts Mutual Life Insurance Company	AA+
95 \$2,328,547	Μ	85	50.8	Metropolitan Life Insurance Company	AA-
96 \$2,000,000	Μ	85	50.8	Metropolitan Life Insurance Company	AA-
97 \$1,000,000	Μ	85	31.5	Transamerica Life Insurance Company	AA-
98 \$500,000	Μ	85	88.9	Metropolitan Life Insurance Company	AA-
99 \$2,000,000	Μ	85	68.6	Jefferson-Pilot Life Insurance Company	AA-
100\$3,000,000	F	85	78.1	Transamerica Life Insurance Company	AA-
101\$1,800,000	Μ	85	58.7	John Hancock Variable Life Insurance Company	AA-
102\$2,000,000	Μ	85	71.2	AXA Equitable Life Insurance Company	A+
103\$1,750,000	Μ	85	71.2	AXA Equitable Life Insurance Company	A+

Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
104\$2,000,000	М	85	40.9	Transamerica Life Insurance Company	AA-
105\$1,425,000	M	85	89.1	John Hancock Life Insurance Company (U.S.A)	AA-
106\$1,500,000	М	84	55.9	Transamerica Life Insurance Company	AA-
107\$1,500,000	F	84	116.2	Lincoln Benefit Life Company	BBB+
108\$3,750,000	М	84	82.8	AXA Equitable Life Insurance Company	A+
109\$1,000,000	М	84	66.8	John Hancock Life Insurance Company (U.S.A)	AA-
110\$2,000,000	F	84	92.1	AXA Equitable Life Insurance Company	A+
111\$1,000,000	М	84	60.9	ING Life Insurance and Annuity Company	A-
112\$3,000,000	F	84	90.6	Sun Life Assurance Company of Canada (U.S.)	AA-
113\$829,022	F	84	31.1	Hartford Life and Annuity Insurance Company	BBB+
114\$1,500,000	М	84	86.3	AXA Equitable Life Insurance Company	A+
115\$5,000,000	М	84	96.2	ING Life Insurance and Annuity Company	A-
116\$1,500,000	М	84	55.7	ING Life Insurance and Annuity Company	A-
117\$1,500,000	М	84	55.7	ING Life Insurance and Annuity Company	A-
118\$5,000,000	М	84	80.1	ING Life Insurance and Annuity Company	A-
119\$500,000	М	84	47.6	Genworth Life Insurance Company	A-
120\$1,000,000	М	84	53.8	John Hancock Life Insurance Company (U.S.A)	AA-
121\$4,000,000	F	84	56.2	ING Life Insurance and Annuity Company	A-
122\$5,000,000	F	84	99.7	American General Life Insurance Company	A+
123\$3,500,000	F	84	115.0	Lincoln Benefit Life Company	BBB+
124\$5,000,000	F	83	104.2	AXA Equitable Life Insurance Company	A+
125\$1,000,000	F	83	90.6	John Hancock Life Insurance Company (U.S.A)	AA-
126\$6,000,000	F	83	118.0	American General Life Insurance Company	A+
127\$5,000,000	М	83	72.6	AXA Equitable Life Insurance Company	A+
128\$2,000,000	М	83	46.1	National Life Insurance Company	А
129\$4,200,000	F	83	126.5	Transamerica Life Insurance Company	AA-
130\$750,000	Μ	83	96.1	West Coast Life Insurance Company	AA-
131\$4,000,000	М	83	43.3	John Hancock Life Insurance Company (U.S.A)	AA-
132\$1,000,000	М	83	89.0	John Hancock Life Insurance Company (U.S.A)	AA-
133\$2,000,000	F	83	105.8	Lincoln Benefit Life Company	BBB+
134\$5,000,000	М	83	81.8	Jefferson-Pilot Life Insurance Company	AA-
135\$2,700,000	М	83	68.6	John Hancock Life Insurance Company (U.S.A)	AA-
136\$7,600,000	F	83	105.3	Transamerica Life Insurance Company	AA-
137\$2,500,000	F	83	70.5	American General Life Insurance Company	A+
138\$2,500,000	М	83	66.3	AXA Equitable Life Insurance Company	A+
139\$3,000,000	М	83	66.3	Lincoln National Life Insurance Company	AA-
140\$2,000,000	Μ	83	93.2	Pacific Life Insurance Company	A+
141\$3,000,000	F	83	50.3	AXA Equitable Life Insurance Company	A+
142\$1,703,959	Μ	83	74.5	Jefferson-Pilot Life Insurance Company	AA-
143\$3,000,000	Μ	83	68.2	Metropolitan Life Insurance Company	AA-
144\$500,000	Μ	83	23.9	Great Southern Life Insurance Company	N/A
145\$1,000,000	Μ	83	64.8	Hartford Life and Annuity Insurance Company	BBB+
146\$10,000,000	F	83	64.6	American National Insurance Company	А
147\$500,000	Μ	83	30.8	West Coast Life Insurance Company	AA-
148\$3,500,000	F	82	100.1	Jefferson-Pilot Life Insurance Company	AA-
149\$500,000	Μ	82	108.1	Metropolitan Life Insurance Company	AA-

150\$1,000,000	М	82	76.1	Lincoln National Life Insurance Company	AA-
151\$3,000,000	Μ	82	46.9	U.S. Financial Life Insurance Company	A+
152\$1,900,000	Μ	82	73.4	American National Insurance Company	А
153\$500,000	Μ	82	52.5	New York Life Insurance Company	AA+
154\$500,000	Μ	82	52.5	New York Life Insurance Company	AA+
155\$5,000,000	Μ	82	80.7	AXA Equitable Life Insurance Company	A+
156\$250,000	Μ	82	38.5	Jackson National Life Insurance Company	AA
157\$1,500,000	Μ	82	83.0	Jefferson-Pilot Life Insurance Company	AA-
158\$3,500,000	F	82	96.2	AXA Equitable Life Insurance Company	A+
159\$5,000,000	F	82	83.1	Sun Life Assurance Company of Canada (U.S.)	AA-
160\$3,000,000	F	82	101.5	MetLife Investors USA Insurance Company	AA-

Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
161\$750,000	Μ	82	89.4	John Hancock Life Insurance Company (U.S.A)	AA-
162\$4,500,000	М	82	81.3	AXA Equitable Life Insurance Company	A+
163\$1,250,000	F	82	68.4	Columbus Life Insurance Company	AA
164\$2,275,000	М	82	98.7	ING Life Insurance and Annuity Company	A-
165\$10,000,000		82	86.7	AXA Equitable Life Insurance Company	A+
166\$2,300,000	М	82	26.8	American General Life Insurance Company	A+
167\$3,500,000	М	82	79.7	AXA Equitable Life Insurance Company	A+
168\$6,217,200	F	82	113.9	Phoenix Life Insurance Company	B+
169\$2,500,000	F	82	79.6	ING Life Insurance and Annuity Company	A-
170\$5,000,000	F	82	64.4	Massachusetts Mutual Life Insurance Company	AA+
171\$1,500,000	Μ	82	31.1	Pacific Life Insurance Company	A+
172\$2,000,000	F	82	105.6	Jefferson-Pilot Life Insurance Company	AA-
173\$5,000,000	Μ	82	91.5	Jefferson-Pilot Life Insurance Company	AA-
174\$3,000,000	Μ	81	75.7	Protective Life Insurance Company	AA-
175\$1,500,000	Μ	81	75.7	American General Life Insurance Company	A+
176\$2,000,000	F	81	124.9	Transamerica Life Insurance Company	AA-
177\$1,500,000	Μ	81	63.6	Pacific Life Insurance Company	A+
178\$5,000,000	Μ	81	118.4	American General Life Insurance Company	A+
179\$1,995,000	F	81	88.2	Transamerica Life Insurance Company	AA-
180\$4,000,000	Μ	81	63.8	Jefferson-Pilot Life Insurance Company	AA-
181\$10,000,000	Μ	81	88.8	New York Life Insurance Company	AA+
182\$5,000,000	Μ	81	83.4	Transamerica Life Insurance Company	AA-
183\$2,000,000	Μ	81	78.9	Ohio National Life Assurance Corporation	AA-
184\$1,000,000	Μ	81	78.9	Ohio National Life Assurance Corporation	AA-
185\$350,000	Μ	81	42.5	Reassure America Life Insurance Company	AA
186\$5,000,000	Μ	80	101.2	AXA Equitable Life Insurance Company	A+
187\$8,000,000	Μ	80	92.6	AXA Equitable Life Insurance Company	A+
188\$550,000	Μ	80	113.1	Genworth Life Insurance Company	A-
189\$1,680,000	F	80	77.0	AXA Equitable Life Insurance Company	A+
190\$1,000,000	F	80	106.5	Jefferson-Pilot Life Insurance Company	AA-
191\$1,250,000	Μ	80	110.3	Metropolitan Life Insurance Company	AA-
192\$1,000,000	Μ	80	74.7	AXA Equitable Life Insurance Company	A+
193\$1,250,000	F	80	84.1	Principal Life Insurance Company	A+
194\$1,000,000	Μ	80	65.2	AXA Equitable Life Insurance Company	A+
195\$3,000,000	Μ	80	108.6	John Hancock Life Insurance Company (U.S.A)	AA-
196\$2,000,000	Μ	80	48.1	Jefferson-Pilot Life Insurance Company	AA-
197\$1,750,000	Μ	80	92.6	AXA Equitable Life Insurance Company	A+
198\$5,000,000	Μ	80	82.0	AXA Equitable Life Insurance Company	A+
199\$250,000	Μ	80	89.6	American General Life Insurance Company	A+
200\$10,000,000	Μ	80	124.0	John Hancock Life Insurance Company (U.S.A)	AA-
201\$3,000,000	Μ	80	121.4	Principal Life Insurance Company	A+
202\$1,210,000	Μ	80	73.2	Lincoln National Life Insurance Company	AA-
203\$3,000,000	F	80	116.7	West Coast Life Insurance Company	AA-
204\$7,000,000	Μ	80	96.6	Genworth Life Insurance Company	A-
205\$3,000,000	Μ	79	101.6	ING Life Insurance and Annuity Company	A-
206\$4,000,000	Μ	79	91.0	Jefferson-Pilot Life Insurance Company	AA-

207\$5,000,000	Μ	79	101.8	John Hancock Life Insurance Company (U.S.A)	AA-
208\$2,000,000	Μ	79	35.0	Metropolitan Life Insurance Company	AA-
209\$6,000,000	Μ	79	134.7	AXA Equitable Life Insurance Company	A+
210\$130,000	Μ	79	59.2	Genworth Life Insurance Company	A-
211\$1,000,000	Μ	79	135.7	Empire General Life Assurance Corporation	AA-
212\$2,000,000	F	79	99.9	Pacific Life Insurance Company	A+
213\$4,300,000	F	79	121.9	American National Insurance Company	А
214\$2,000,000	F	79	98.4	Transamerica Life Insurance Company	AA-
215\$5,000,000	Μ	79	104.0	AXA Equitable Life Insurance Company	A+
216\$5,000,000	Μ	79	104.0	AXA Equitable Life Insurance Company	A+
217\$500,000	Μ	79	56.8	Transamerica Life Insurance Company	AA-

Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
218\$3,000,000	М	78	51.4	Pacific Life Insurance Company	A+
219\$3,000,000		78	51.4	Minnesota Life Insurance Company	A+
220\$3,000,000		78	51.4	Prudential Life Insurance Company	AA-
221\$5,000,000		78	89.4	Pacific Life Insurance Company	A+
222\$5,000,000		78	89.4	Pacific Life Insurance Company	A+
223\$3,601,500		78	105.6	Transamerica Life Insurance Company	AA-
224\$1,000,000		78	102.3	Sun Life Assurance Company of Canada (U.S.)	AA-
225\$5,000,000	М	78	100.4	John Hancock Life Insurance Company (U.S.A)	AA-
226\$5,000,000	М	78	125.2	Principal Life Insurance Company	A+
227\$1,009,467	Μ	78	58.7	John Hancock Life Insurance Company (U.S.A)	AA-
228\$7,000,000	М	78	97.4	Lincoln Benefit Life Company	BBB+
229\$5,000,000	М	78	66.8	John Hancock Life Insurance Company (U.S.A)	AA-
230\$476,574	Μ	78	83.2	Transamerica Life Insurance Company	AA-
231\$2,250,000	М	78	105.9	Massachusetts Mutual Life Insurance Company	AA+
232\$1,000,000	Μ	78	122.6	Metropolitan Life Insurance Company	AA-
233\$6,000,000	Μ	78	119.1	AXA Equitable Life Insurance Company	A+
234\$5,000,000	F	78	129.0	ING Life Insurance and Annuity Company	A-
235\$750,000	Μ	78	80.6	Lincoln National Life Insurance Company	AA-
236\$3,000,000	Μ	78	107.4	Principal Life Insurance Company	A+
237\$5,000,000	Μ	77	131.0	Jefferson-Pilot Life Insurance Company	AA-
238\$5,000,000	Μ	77	89.3	John Hancock Life Insurance Company (U.S.A)	AA-
239\$500,000	Μ	77	77.7	John Hancock Life Insurance Company (U.S.A)	AA-
240\$1,000,000	Μ	77	121.3	Metropolitan Life Insurance Company	AA-
241\$4,000,000	Μ	77	59.8	MetLife Investors USA Insurance Company	AA-
242\$2,500,000	Μ	77	99.5	Massachusetts Mutual Life Insurance Company	AA+
243\$2,500,000	Μ	77	99.5	Massachusetts Mutual Life Insurance Company	AA+
244\$500,000	F	77	128.9	Columbus Life Insurance Company	AA
245\$1,750,000	М	77	73.6	John Hancock Life Insurance Company (U.S.A)	AA-
246\$5,000,000	М	77	116.1	Transamerica Life Insurance Company	AA-
247\$3,750,000		77	68.8	AXA Equitable Life Insurance Company	A+
248\$2,000,000		77	67.4	Transamerica Life Insurance Company	AA-
249\$2,840,000		76	111.0	Transamerica Life Insurance Company	AA-
250\$4,000,000		76	79.4	Massachusetts Mutual Life Insurance Company	AA+
251\$750,000	Μ	76	16.5	U.S. Financial Life Insurance Company	A+
252\$1,000,000		76	87.2	John Hancock Life Insurance Company (U.S.A)	AA-
253\$490,620	Μ	76	99.6	Ameritas Life Insurance Corporation	A+
254\$600,000	Μ	76	96.6	Protective Life Insurance Company	AA-
255\$5,000,000		75	163.8	Prudential Life Insurance Company	AA-
256\$3,000,000		75	117.7	Protective Life Insurance Company	AA-
257\$2,000,000		75	133.9	Aviva Life Insurance Company	A-
258\$7,000,000		75	137.0	Pacific Life Insurance Company	A+
259\$850,000	M	75	79.4	New York Life Insurance Company	AA+
260\$1,000,000		75	96.3	Pacific Life Insurance Company	A+
261\$5,000,000		75	71.4	West Coast Life Insurance Company	AA-
262\$3,000,000		74	67.6	Aviva Life Insurance Company	A-
263\$200,000	М	74	83.0	ING Life Insurance and Annuity Company	A-

264\$8,000,000 M	74	117.6	Metropolitan Life Insurance Company	AA-
265\$4,000,000 F	74	159.5	American General Life Insurance Company	A+
266\$5,000,000 M	74	42.8	Lincoln Benefit Life Company	BBB+
267\$3,000,000 F	74	131.0	General American Life Insurance Company	AA-
268\$300,000 M	73	25.3	Lincoln National Life Insurance Company	AA-
269\$2,000,000 M	73	113.5	American General Life Insurance Company	A+
270\$500,000 M	72	47.1	Midland National Life Insurance Company	A+
271\$3,000,000 M	72	89.0	AXA Equitable Life Insurance Company	A+
272\$1,000,000 M	72	82.5	United of Omaha Life Insurance Company	A+
273\$2,500,000 M	71	113.2	American General Life Insurance Company	A+
274\$1,167,000 M	71	38.7	Transamerica Life Insurance Company	AA-

Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
275\$1,500,000	М	71	128.3	Metropolitan Life Insurance Company	AA-
276\$3,000,000	М	70	91.5	John Hancock Life Insurance Company (U.S.A)	AA-
277\$2,000,000	М	70	118.8	New York Life Insurance Company	AA+
278\$2,000,000	М	70	118.8	New York Life Insurance Company	AA+
279\$2,500,000	М	70	130.2	Lincoln National Life Insurance Company	AA-
280\$2,500,000	М	70	130.2	John Hancock Life Insurance Company (U.S.A)	AA-
281\$600,000	М	70	101.9	AXA Equitable Life Insurance Company	A+
282\$500,000	М	69	109.6	Transamerica Life Insurance Company	AA-
283\$500,000	М	69	109.6	North American Company for Life And Health Insurance	A+
284\$2,000,000	М	67	131.7	Transamerica Life Insurance Company	AA-
285\$1,000,000	М	67	131.7	Genworth Life Insurance Company	A-
286\$156,538	F	67	123.9	New York Life Insurance Company	AA+
287\$2,000,000	М	67	64.0	MetLife Investors USA Insurance Company	AA-
288\$2,000,000	М	67	64.0	MetLife Investors USA Insurance Company	AA-
289\$1,000,000	М	65	61.5	Lincoln National Life Insurance Company	AA-
\$787,963,84	1				

(1) The insured's age is current as of the measurement date.

The insured's life expectancy estimate, other than for a small face value insurance policy is the average of two life (2) expectancy estimates provided by independent third-party medical actuarial underwriting firms actuarially adjusted through the measurement date.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance the objectives of the control system are met.

As of September 30, 2014, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of our disclosure controls and procedures as such term is defined in Rule 13a-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on that evaluation, our Chief

Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Securities Exchange Act of 1934 during the period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15 (f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only with proper authorizations; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management, under the supervision of and with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2013 based on criteria for effective control over financial reporting set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in "*Internal Control—Integrated Framework*". Based on this assessment, our management concluded that, as of the evaluation date, we maintained effective internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, the reader should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013. There have been no material changes in the Company's risk factors from those disclosed in Part I, Item 1A, of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 with the exception of the additional items described below.

Risks Related to Ownership of Our Common Stock

The price of our common stock may be subject to wide fluctuations.

Before our initial public offering and listing on The NASDAQ Capital Market, there was no public market for our common stock, and an active trading market for our common stock may not develop. Our stockholders may not be able to sell their shares quickly or at the current market price if trading in our stock is not active. The initial public offering price for our common stock was arbitrarily determined based on negotiations between us and the underwriters. The market price of our common stock will likely vary from the initial offering price and is likely to be highly volatile and subject to wide fluctuations in response to a variety of factors and risks, many of which are beyond our control. In addition to the risks noted elsewhere in this prospectus, some of the other factors affecting our stock price may include:

variations in our operating results;

the level and quality of securities analysts' coverage for our common stock;

announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;

announcements by third parties of significant claims or proceedings against us; and

future sales of our common stock.

For these reasons, comparing our operating results on a period-to-period basis may not be meaningful, and our stockholders should not rely on past results as an indication of future performance. In the past, following periods of volatility in the market price of a public company's securities, securities class action litigation has often been instituted against the public company. Regardless of its outcome, this type of litigation could result in substantial costs to us and a likely diversion of our management's attention. Our stockholders may not receive a positive return on their investment when they sell their shares and may lose the entire amount of their investment.

The concentration of our common stock ownership by our current management will limit the ability of our stockholders to influence corporate matters.

Our directors and executive officers beneficially own and will be able to vote in the aggregate approximately 78.8% of our issued and outstanding common stock. As such, our directors and executive officers, as stockholders, have the ability to elect or remove any or all of our directors and to control substantially all corporate activities, including the outcome of tender offers, mergers, proxy contests or other purchases of common stock that could give our stockholders the opportunity to realize a premium over the then-prevailing market price for their shares of common stock. This concentrated control will limit the ability of our stockholders to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. In addition, such concentrated control could discourage others from initiating changes of control. In such cases, the perception of our prospects in the market may be adversely affected and the market price of our common stock may decline.

Our Board of Directors' ability to issue "blank check" preferred stock and any anti-takeover provisions we adopt may depress the value of our common stock.

Our Certificate of Incorporation authorizes 40,000,000 shares of "blank check" preferred stock. This means that our Board of Directors has the power to issue any or all of the shares of such preferred stock, including the authority to establish one or more series and to fix the powers, preferences, rights and limitations of such class or series, without seeking stockholder approval, subject to certain limitations on this power under the listing requirements of The NASDAQ Stock Market, Inc. The authority of our Board of Directors to issue "blank check" preferred stock, along with any future anti-takeover measures we may adopt, may, in certain circumstances, delay, deter or prevent takeover attempts and other changes in control of our company that are not approved by our Board of Directors. As a result, our stockholders may lose opportunities to dispose of their shares at favorable prices generally available in takeover attempts or that may be available under a merger proposal and the market price of our common stock and the voting and other rights of our stockholders may also be affected. See "Description of Capital Stock."

Our common stock could be delisted from The NASDAQ Capital Market, which delisting could hinder the ability of our stockholders to obtain accurate quotations on the price of our common stock, or dispose of our common stock in the secondary market.

Our common stock started trading on The NASDAQ Capital Market effective September 25, 2014. However, we cannot guarantee that our common stock will continue to be so listed or that an active public market for our common stock will develop. In order to maintain any listing on The NASDAQ Capital Market, our common stock must sustain a minimum bid price of at least \$1.00 per share and we must satisfy the other requirements for continued listing on The NASDAQ Capital Market. In the event our common stock is delisted from The NASDAQ Capital Market, trading in our common stock could thereafter be conducted in the over-the-counter markets in the so-called pink sheets (currently called the "OTC Markets") or the National Association of Securities Dealer's OTC Bulletin Board. In such event, the liquidity of our common stock would likely be impaired, not only in the number of shares which could be bought and sold, but also through delays in the timing of the transactions, and there would likely be a reduction in the coverage of our company by security analysts and the news media, thereby resulting in lower prices for our common stock than might otherwise prevail.

Because we do not intend to pay dividends on our common stock, our stockholders must rely on stock appreciation for any return on their investment.

We presently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. As a result, our stockholders must rely on stock appreciation and a liquid trading market for any return on your investment. If an active and liquid trading market does not develop, our stockholders may be unable to sell their shares of common stock at or above the initial public offering price or at the time they would like to sell.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Use of Proceeds – Initial Public Offering of Common Stock

Our Form S-1 registration statement relating to the initial public offering of our common stock (File No. 333-195505) was declared effective by the SEC on September 18, 2014. Newport Coast Securities, Inc., Axiom Capital Management, Inc. and Newbridge Securities Corporation acted as the underwriters for the offering, with Newport Coast Securities, Inc. acting as representative for the underwriters. In the initial public offering, 800,000 shares of common stock that were sold at a price of \$12.50 per share, and the aggregate offering price for the shares was \$10.0 million. All of the shares of common stock were sold by the Company and no selling stockholders participated in the offering. The offering did not terminate until after the sale of all 800,000 shares of common stock registered on the registration statement. The closing of the initial public offering occurred on September 24, 2014, and shares of our common stock began trading on The NASDAQ Capital Market effective September 25, 2014.

The initial public offering generated net proceeds of approximately \$9.03 million after the deduction of underwriting commissions, discounts and expense reimbursements. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates), persons owning 10 percent or more of our common stock or any other affiliates. We used our proceeds from the offering to promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in the secondary market for life insurance policies, purchase additional life insurance policies in the secondary market, pay premiums on the company's life insurance policy assets, fund our portfolio operations, and for working capital purposes.

Use of Proceeds – Renewable Secured Debentures

Our Form S-1 registration statement relating to our public offer and sale of "Renewable Secured Debentures" (File Nos. 333-174887 and 333-174887-01) was declared effective by the SEC on January 31, 2012, and our offering of debentures commenced on such date. The debentures are secured in part by a guarantee from our subsidiary GWG

Life and an associated grant of a security interest in substantially all of the assets of GWG Life, which guarantee was also registered as a security under the referenced registration statement. Arque Capital Ltd. serves as our managing broker-dealer and underwriter for the offering.

The registration statement covers up to \$250 million in principal amount of debentures. From January 31, 2012 through September 30, 2014, we sold a total of \$224,738,000 in principal amount of debentures, and incurred associated underwriting commissions, and expenses paid or payable to underwriters in the amount of \$10,602,000 of which \$4,865,000 was amortized. As of September 30, 2014 we had \$173,245,000 of debentures in force plus \$1,679,000 of subscriptions in process, less unamortized selling costs of \$5,737,000, resulting in aggregate net proceeds of \$169,187,000. None of the payments for offering expenses were directly or indirectly made to our directors or officers (or their associates), our affiliates, or to persons owning 10% or more of any class of our equity securities.

Our goal is to use a majority of the net proceeds from the sale of Renewable Secured Debentures to purchase additional life insurance policies in the secondary market. The amount of proceeds we apply towards purchasing additional life insurance policies will depend, among other things, on how long the debentures are offered, the amount of net proceeds that we receive from the sale of debentures being offered, the existence and timing of opportunities to expand our portfolio of insurance policy assets, our cash needs for certain other expenditures we anticipate incurring in connection with this offering and in connection with our business, and the availability of other sources of cash (e.g., our revolving credit facility).

We currently expect to allocate net offering proceeds (assuming the maximum amount of commissions, fees and allowances of 8.00% of the aggregate principal amount of Renewable Secured Debentures sold) as follows, based upon various assumed amounts of gross proceeds that we receive from the proceeds of the offering:

	Gross Offering	Proceeds	S					
	\$250,000,000		\$125,000,000		\$62,500,000		\$25,000,000	
Net Offering Proceeds	229,000,000	100%	114,000,000	100%	56,500,000	100%	22,000,000	100%
Purchase Policies	178,620,000	78 %	82,080,000	72 %	38,420,000	68 %	10,560,000	48 %
Payment of Premiums	18,320,000	8 %	11,400,000	10 %	7,910,000	14 %	4,180,000	19 %
Payment of Principal and Interest	16,030,000	7 %	11,400,000	10 %	5,650,000	10 %	4,180,000	19 %
Other Expenditures	16,030,000	7 %	9,120,000	8 %	4,520,000	8 %	3,080,000	14 %

Net offering proceeds not immediately applied to the uses summarized above will be invested short-term investments such as money market funds, commercial paper, U.S. Treasury Bills and similar securities investments pending their use.

The actual use of proceeds from the sale of Renewable Secured Debentures from January 31, 2012 to September 30, 2014 is as follows:

Gross Offering Proceeds	\$189,870,000	
Net Offering Proceeds	178,453,000	
Held in Short-Term Investments	19,867,000	
Net Offering Proceeds Used	\$158,586,000	100%
Purchase Policies	67,954,000	43 %
Payment of Premiums	29,387,000	18 %
Payment of Principal and Interest	45,587,000	29 %
Other Expenditures	15,658,000	10 %

ITEM 5. OTHER INFORMATION

Regulatory Update

On November 5, 2014, the staff of the Securities and Exchange Commission, Division of Enforcement, advised us in writing that its investigation, which we previously disclosed in a Quarterly Report on Form 10-Q filed on October 30, 2013, has been closed and that the staff does not intend to recommend any enforcement action by the Commission against the Company.

New Executive Officer

On November 13, 2014, the Company appointed Michael D. Freedman to serve as the Company's President.

Mr. Freedman, 51, served as the Senior Vice President of Government Affairs at Coventry First, LLC, a participant in the life settlement industry, from June 2002 to December 2013. From In January 2014, Mr. Freedman founded Sentinel Solutions, LLC, a strategic provider of services to clients in the life settlement and related industries, including insurance, financial services and other innovative business interests, which he continues to own. In September 2014, Mr. Freedman joined GWG Holdings, Inc. as its Executive Vice President and General Counsel.

In connection with the appointment of Mr. Freedman, Steven F. Sabes resigned his position as President and was appointed Executive Vice President of Originations and Servicing.

Amendment to Bylaws

On November 13, 2014, the Board of Directors of the Company amended the Company's bylaws.

The amendment provides that, unless the Company consents in writing to the selection of an alternative forum, any state or federal court located within the State of Minnesota shall be the sole and exclusive forum for any claim or counterclaim, including, without limitation, (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company's stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv) any action asserting a claim governed by the internal affairs doctrine.

The amendment further provides: (a) for fee-shifting with respect to certain types of litigation brought against the Company and/or any stockholder where the claiming parties do not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought; and (b) for limitations on the initiation of certain private rights of action unless the claiming stockholder delivers written consents from beneficial stockholders owning at least three percent (3%) of the outstanding shares of the Company as of a specified date.

The foregoing description of the amendment to the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of such amendment (a copy of which is filed as Exhibit 3.1 to this report and incorporated herein by reference).

ITEM 6. EXHIBITS

Exhibit

- 3.1 Amendment to Bylaws, as adopted on November 13, 2014 (*filed herewith*).
- 31.1 Section 302 Certification of the Chief Executive Officer (*filed herewith*).
- 31.2 Section 302 Certification of the Chief Financial Officer (*filed herewith*).
- 32 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (*filed herewith*).
- 99.1 Letter from Model Actuarial Pricing Systems, dated October 24, 2014 (*filed herewith*).
- 101.INS XBRL Instance Document (filed herewith).
- 101.SCH XBRL Schema Document (filed herewith).
- 101.CAL XBRL Calculation Linkbase Document (filed herewith).
- 101.DEF XBRL Definition Linkbase Document (filed herewith).

- 101.LAB XBRL Label Linkbase Document (filed herewith).
- 101.PRE XBRL Presentation Linkbase Document (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GWG HOLDINGS, INC.

Date: November 13, 2014 By:/s/ Jon R. Sabes Chief Executive Officer

Date: November 13, 2014 By:/s/ William B. Acheson Chief Financial Officer